Prehospital management of acute myocardial infarction in a helicopter-based emergency medical service system by Väisänen, Olli
 Department of Anaesthesiology and  
Intensive Care Medicine 
University of Helsinki 
Finland 
 
 
 
 
 
 
 
Prehospital Management of Acute Myocardial Infarction in a 
Helicopter-Based Emergency Medical Service System 
 
 
 
 
 
Olli Väisänen 
 
 
 
 
 
 
 
 
 
 
Academic dissertation 
 
 
 
 
To be publicly discussed, with the permission of the Medical Faculty of the University of 
Helsinki, in the auditorium B of the Department of Otorhinolaryngology, 
 Haartmanninkatu 4 E (building 12),  
on 26th November, 2005, at 12 noon. 
 
 
 
 
Helsinki 2005 
  
 
Supervisors 
 
Docent Tom Silfvast, M.D., Ph.D. 
Department of Anaesthesiology and Intensive Care Medicine  
Helsinki University Central Hospital 
Finland 
 
Docent Markku Mäkijärvi, M.D., Ph.D.  
Department of Medicine, Division of Cardiology and Biomag Laboratory 
Helsinki University Central Hospital 
Finland 
 
 
Reviewers 
 
Docent Markku Kuisma, M.D., Ph.D. 
Helsinki Emergency Medical Services 
Helsinki University Central Hospital 
Finland 
 
Docent Pekka Raatikainen, M.D., Ph.D. 
Department of Cardiology 
Oulu University Hospital 
Finland 
 
 
 
Official opponent 
 
Docent Tomas Jernberg, M.D., Ph.D. 
Department of Cardiology 
Karolinska Institute, Stockholm 
Sweden 
 
 
 
Cover: Oona Loman 
Cover picture: ”Kopteri” by Mirka Väisänen, 2005 
 
 
 
 
ISBN 952-91-9514-1 
ISBN 952-10-2788-6 (PDF) 
 
Yliopistopaino 
Helsinki 2005 
 
 
 
  
 
 
 
CONTENTS 
 
ABSTRACT...........................................................................................................................5 
LIST OF ORIGINAL PUBLICATIONS ................................................................................7 
ABBREVIATIONS................................................................................................................8 
1. INTRODUCTION..............................................................................................................9 
2. REVIEW OF THE LITERATURE ...................................................................................11 
2.1. Emergency Medical Service (EMS) systems...............................................................11 
2.1.1. Historical aspects .................................................................................................11 
2.1.2. Structure of EMS system in Finland .....................................................................12 
2.2. Coronary Heart Disease (CHD) ..................................................................................16 
2.2.1. Progression of the disease.....................................................................................16 
2.2.2. Risk factors of atherosclerotic disease ..................................................................17 
2.2.3. Acute Coronary Syndromes (ACS).......................................................................18 
2.2.4. Thrombolytic therapy ...........................................................................................20 
2.2.5. Prehospital thrombolysis (PHT)............................................................................28 
2.2.6. Percutaneous coronary intervention (PCI).............................................................33 
3. AIMS OF THE STUDY ...................................................................................................36 
4. MATERIALS AND METHODS ......................................................................................37 
4.1. EMS systems in Helsinki, Turku and Pirkanmaa areas................................................37 
4.2. Patients.......................................................................................................................38 
4.3. Study protocols and treatments ...................................................................................38 
4.3.1. Electrocardiogram transmission (I) .......................................................................38 
4.3.2. Influence of physician involvement on management of ST-elevation myocardial 
infarction (II) .................................................................................................................40 
4.3.3. Thrombolytic therapy performed by a ship’s nurse with on-line physician 
consultation (III) ............................................................................................................41 
4.3.4. Evaluation of arrhythmias and haemodynamic effects (IV)...................................41 
4.3.5. Quality of life of the elderly patients (V) ..............................................................42 
4.3.6. Ethical aspects......................................................................................................42 
4.3.7. Statistical methods................................................................................................43 
5. RESULTS ........................................................................................................................44 
  
 
5.1. Transmission of the electrocardiogram (I)...................................................................44 
5.2. Influence of physician-directed EMS on management of ST-elevation myocardial 
infarction (II, III)...............................................................................................................45 
5.3. Evaluation of adverse events (IV) ...............................................................................46 
5.4. Evaluation of the quality of life of the elderly patients (V)..........................................49 
6. DISCUSSION ..................................................................................................................51 
6.1. Transmission of the electrocardiogram .......................................................................51 
6.2. Influence of physician involvement ............................................................................51 
6.3. Consultation possibilities for nurses and paramedics to perform prehospital 
thrombolysis......................................................................................................................52 
6.4. Delays in prehospital thrombolysis .............................................................................53 
6.5. Complications and adverse effects of prehospital thrombolysis...................................54 
6.6. Elderly patients and prehospital thrombolysis .............................................................56 
6.7. Prehospital thrombolysis vs. percutaneous coronary intervention................................58 
7. LIMITATIONS OF THE STUDY ....................................................................................59 
8. CONCLUSIONS ..............................................................................................................60 
9. FUTURE PERSPECTIVES..............................................................................................61 
9.1. Physician involvement in the EMS systems and EMS co-operation with the Invasive 
Cardiology Units ...............................................................................................................61 
9.2. Reperfusion strategies in the EMS systems and PHT performed by paramedics ..........61 
9.3. Consultation possibilities for prehospital personnel.....................................................62 
9.4. Helicopter Emergency Medical Service system in Finland..........................................62 
ACKNOWLEDGEMENTS..................................................................................................63 
REFERENCES.....................................................................................................................64 
INQUIRY FORMS...............................................................................................................79 
Barthel- rehabilitation index ..............................................................................................79 
Beck Depression Inventory (BDI) .....................................................................................80 
  
 
5 
ABSTRACT 
Background: Coronary heart disease (CHD) is a major health problem in Finland. 
Approximately 12 000 patients suffer from acute myocardial infarction (AMI) every year. The 
one-month mortality is 18 %, increasing to 28 % during the first year. The time from 
occlusion of the coronary artery to the reperfusion therapy is the most important contributory 
factor for saving the myocardium from infarction. Accurate prehospital management shortens 
the delays to therapy and may improve the recovery of patients suffering from AMI. 
 
Aim: The purpose of this study was to evaluate the prehospital management of AMI provided 
by a helicopter emergency medical service (HEMS) system.  
 
Material and methods: The reliability, speed and quality of different transmitting and 
receiving facsimile devices were studied by transmitting 18 electrocardiograms (ECG) with 
four transmitting devices into an advanced mobile phone and to an ordinary table fax (study 
I). The impact of the physician emergency medical service (EMS) system on treatment of ST-
elevation myocardial infarction (STEMI) patients was compared to a non-physician EMS 
system with 641 retrospective patients (study II). Arrhythmias and haemodynamic adverse 
events during and after the prehospital thrombolysis (PHT) were prospectively studied in 
early (pain-to-therapy time < 90 min) and late (> 90 min) study groups with 226 consecutive 
patients treated by two HEMS systems (study IV). The recovery and the long-term outcome 
of the elderly (> 65 years old) patients suffering from STEMI were investigated in 219 
prospective patients (study V). Finally, two case reports are described to demonstrate on-line 
consultation between the HEMS physician and a ship’s nurse during PHT of STEMI 
complicated by ventricular fibrillation (study III). 
 
Results: ECG transmission times from different facsimile devices to an advanced mobile 
phone and conventional fax were comparable. Only in transmissions via a satellite phone 
system was the conventional facsimile system faster (114 +  21 s vs. 97  +  20 s, (mean + SD), 
p=0.01). All transmitted ECGs except one were clinically usable (study I). 
Patients treated by physician EMS received PHT earlier than in non-physician EMS (124 + 
101 min (25-723) vs. 196 + 150 min (12-835), (mean + SD (range)), p<0.001). Physician-
directed EMS was also able to give PHT more often for patients successfully resuscitated 
  
 
6 
from sudden cardiac death caused by STEMI (20 % vs. 0.5 % from all patients, p<0.001) 
(study II).  
Arrhythmias and haemodynamic adverse events occurred in 39 % of all patients (40 % in the 
late group and 38 % in the early group). From these patients only a third needed treatment and 
the response to treatment was good. Ventricular extrasystoles without any need for treatment 
were the most common arrhythmia. Fourteen per cent of patients were hypotensive at the time 
EMS arrived and 7 % became hypotensive after PHT. Fifteen patients received PHT after 
cardiopulmonary resuscitation. Four of these patients had arrhythmias and six patients became 
hypotensive after PHT. The adverse events were not related to the timing of PHT or to the 
duration of pain (study IV). 
The pain-to-therapy times between the younger and the elderly patients were equal (108 + 93 
min vs. 108 + 70 min, respectively). The Barthel Daily Living Index and the Beck Depression 
Inventory (BDI) (depression, if BDI > 10) showed no differences between the groups (< 65 
years: 99 + 5 (range 65 - 100) vs. > 65 years: 98 + 12 (10-100); BDI > 10, 18 % vs. 9 %). The 
one-year survival was lower among the elderly (79 % vs. 93 %; p<0.001) (study V). 
 
Conclusions: The transmission of ECGs to the physician’s advanced mobile phone from the 
field is a reliable and feasible method. Via on-line consultation, it is possible to involve a 
physician in the treatment of the patient suffering STEMI outside the normal medical setting. 
The physician-directed EMS is able to treat patients suffering from STEMI more effectively 
and provide thrombolytic therapy for a wider patient group than non-physician EMS. After 
PHT, serious arrhythmias or haemodynamic adverse events are uncommon and treatable even 
by nursing staff. Moreover, elderly patients recover as well as younger patients from STEMI 
after PHT measured by the Barthel Daily Living Index and Beck Depression Inventory. In an 
advanced EMS system, prehospital thrombolytic therapy is a safe and feasible method. If 
proper consultation facilities can be provided for the prehospital personnel, paramedic or 
nurse-initiated thrombolytic therapy for AMI patients is possible.  
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1. INTRODUCTION 
An emergency medical service (EMS) system is a prehospital entity consisting of different 
levels of prehospital medical units: ambulances, medical cars and helicopters. Personnel in the 
EMS systems include emergency medical technicians (EMT), paramedics and physicians 
working in prehospital units, who are dispatched by the dispatching centre. The purpose of the 
EMS system is to provide prehospital medical care for patients with acute illness or injury in 
order to maintain and improve their vital functions before they are admitted to hospital (Black 
and Davies, 2005). 
 
The first steps towards the EMS system were taken in Europe and USA during the 1960s 
(Manegold and Silver, 1967; Nobel, 1966; Pantridge and Geddes, 1967). In Finland, the first 
prehospital physician-staffed EMS system was founded in 1971 in Helsinki (Murtomaa and 
Korttila, 1974; Siltanen, 1978).  
 
One of the major reasons for alerting the EMS is chest pain caused by coronary heart disease 
(CHD) (Hutter and Weaver, 2000). CHD is a severe health problem in Finland. Every year 
12 000 people suffer from acute myocardial infarction (AMI) (Häkkinen et al., 2002; 
Mahonen et al., 2000). Thrombolytic therapy for AMI was introduced in the 1980s in large 
randomized and controlled trials (GISSI, 1986; ISIS-2, 1988). The results of these trials 
showed that thrombolytic therapy improved survival among patients with AMI. The 
importance of the delay from the occlusion of the coronary artery to the thrombolytic therapy 
was also established (GISSI, 1986). The importance of the delays from the start of the pain to 
thrombolytic treatment was also shown in the meta-analysis, where the delay reduction 30–60 
minutes saved 60–80 lives for 1 000 patients (Boersma et al., 1996). To investigate the 
possibilities to reduce the pain-to-therapy time, prehospital thrombolysis (PHT) studies were 
designed and better survival of patients receiving PHT instead of in-hospital thrombolytic 
therapy was shown (Morrison et al., 2000). In Finland, Helsinki EMS introduced PHT by  
participating in the EMIP trial (EMIP, 1993). Thereafter, also some other EMS systems 
started to perform PHT, but in 1995 the pain-to-therapy times were still nearly three hours, 
and only some EMS systems performed PHT in Finland (Hirvonen et al., 1998). PHT 
performed by paramedics is still an underused option in Finland. A probable reason for this is 
that the health-care professionals responsible for prehospital work are afraid of the risk of 
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adverse events such as arrhythmias, haemodynamic disorders and other adverse events which 
have been shown to complicate thrombolytic therapy (ASSENT-2, 1999; GREAT, 1992; 
ISIS-2, 1988). The purpose of this thesis was to evaluate the prehospital management of AMI 
provided by a helicopter emergency medical service (HEMS) system.  
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2. REVIEW OF THE LITERATURE 
 
2.1. Emergency Medical Service (EMS) systems  
 
2.1.1. Historical aspects  
An emergency medical service (EMS) system is an organisation that comprises the 
dispatching centre, ambulance service and other medical rescue units working in the 
prehospital setting. In Europe the first EMS system with mobile intensive care units was 
founded in Belfast, Ireland (Pantridge, 1967). In the USA, the development of the EMS 
systems began at the same time (Manegold and Silver, 1967; Nobel, 1966). In the USA, 
specially trained emergency medical technicians (EMT) work in ambulances at a basic level 
and paramedics at an advanced life support level (Watkins et al., 1975). In Europe the basic 
constructions of EMS systems are the same as in the USA, but some European countries also 
have physicians who attend the prehospital work (Adnet and Lapostolle, 2004). 
 
Helicopters were used for patient transportation for the first time in the Korean conflict, when 
injured soldiers were evacuated from the battle field (Neel, 1955). The use of helicopters in 
military health care was more advanced during the Vietnam war, and the concept of using 
helicopters in civil health care as well is based on those experiences (Neel, 1968). The first 
European helicopter emergency medical service (HEMS) systems were founded in 
Switzerland and Germany at the end of the 1960s (Allgower, 1991), and the first HEMS in 
Nordic Countries (The Norsk Luftambulance) was founded in 1977 in Norway (Langhelle et 
al., 2004). HEMS systems were originally designed to improve the treatment of trauma 
patients by transporting EMS personnel to the patient instead of transporting the patient to the 
hospital (Botha, 1992; Moylan, 1988), but also other medical emergencies such as AMI 
patients could benefit from effective prehospital care provided by HEMS (Bredmose et al., 
2003). Inter-hospital secondary transfers with helicopters are more common in the USA, but 
are also used in Europe (Sollid et al., 2003; Werman et al., 1999). 
 
In Finland, the first 24 h physician-staffed prehospital emergency medical unit was founded in 
Helsinki in 1971 (Murtomaa and Korttila, 1974; Siltanen, 1978).  At first it served as a mobile 
coronary care unit, but in 1972 it started to serve in all emergencies including trauma. In 1992 
the first Finnish HEMS system was founded in the Helsinki area (Medi-Heli 01) to serve 
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approximately 800 000 inhabitants in the Uusimaa area outside the city of Helsinki. Since 
Medi-Heli 01 was founded, several physician-staffed HEMS systems have also been founded 
in Finland (Figure 1). Medi-Heli 01 in the Helsinki area and Medi-Heli 02 in the Turku area 
are the only HEMS units solely for medical emergencies. The other HEMS units serve also as 
search and rescue units.  
 
2.1.2. Structure of EMS system in Finland 
 
Dispatching centre 
 
In Finland the number of dispatching centres has recently been changed and all 15 state-
owned centres will be active by the end of 2005 (Langhelle et al., 2004). After 2006 the 
police, the rescue and fire units as well as all EMS units will be dispatched from the same 
place. The national emergency number 112 will provide help in the future as well.  
 
 
First response 
 
In Finland the fire brigades, the police and the coast guard serve as first response in medical 
emergencies. First response units are dispatched from the dispatching centre. The equipment 
of the first response units varies from simple first aid equipment to semi-automatic 
defibrillators and oxygen delivery possibilities. First response units have radio equipment and 
they are able to contact the EMS unit. A first response unit will never be dispatched to the 
scene alone (Castrén et al., 2004).  
 
 
Basic ambulance level 
 
In Finland, basic ambulances are manned by two EMTs trained either in the National 
Emergency College (1.5 years) or in the Second Degree Health Institutes (2.5 years). They are 
able to perform endotracheal intubation and defibrillation of lifeless patient, open intravenous 
access in conjunction with fluid resuscitation with crystalloids, and can give 10 % glucose 
solution to hypoglycemic patients. Usually they are also allowed to administer intravenous 
adrenaline, oral aspirin and rectal diazepam, if needed. 
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The basic ambulance level is dispatched to the scene, if the risk of vital organ disorder is low 
or if the patient is suffering from vital sign disorder, to assist the paramedics or physician unit. 
Every fire brigade unit in Finland is also equipped with similar medical equipment as basic 
ambulances, and if there is an EMT working in the fire unit, it is able to serve as first response 
at EMT level (Castrén et al., 2004).  
 
 
Paramedic level 
 
Official paramedic education started in Finland in 1998 as a four-year degree in Paramedic 
Science. The education is given in eight Polytechnics in Finland. Common targets in 
Paramedic education has been set by the Ministry of Education and all the institutes must 
follow these targets (Minedu, 2000). National written final tests for all students are under 
construction. Some nurses specialized in emergency care as well as other health professionals 
qualified for prehospital work function at the paramedic level in the EMS services. 
 
Paramedics can treat vital disorders with large variety of medical equipment and drugs. They 
have the possibility, either by themselves or after consultation with a physician, to start 
vasoactive infusions (nitrate, dopamine and adrenaline), administer intravenous analgesics 
and sedatives (morphine, alfentanile, diazepam and lorazepam), beta-blockers or verapamil 
and in some cases start the thrombolytic treatment for AMI, if ordered. They are able to take a 
13-lead electrocardiogram (ECG) from the patient, evaluate it and if necessary send it to the 
physician for re-evaluation. They are able to start Continuous Positive Airway Pressure with a 
mask and in some cases, with on-line consultation, sedate the patient and perform 
endotracheal intubation. Paramedics may use crystalloids and colloids to perform fluid 
resuscitation and they have to be able to perform cardiopulmonary resuscitation with 
endotracheal intubation and all necessary medication (adrenaline, amiodarone). Paramedics 
must have skills for assistance in labour and take care of the newborn, as well as act in other 
pediatric emergencies (Minedu, 2000). 
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Physician-staffed emergency medical units 
 
Most of the physicians working in the EMS are anaesthesiologists or residents in 
anaesthesiology (Langhelle et al., 2004). A physician-staffed EMS is not restricted to trauma 
care and they also attend in medical emergencies. Most of the physicians working in the 
prehospital EMS system have another position in the hospital or in the administration, and 
only limited number of physicians work in EMS full time. The only 24 h physician-staffed 
ground unit is located in Helsinki (Herlitz, 1999) and other physician-staffed ground units in 
Finland are part-time units only. All the HEMS systems also have a medical car, if the 
weather conditions are too severe for flying or if the patient is located near the HEMS base. 
HEMS systems in Finland are run by non-profit organizations. Helsinki city EMS is the only 
24 h physician-staffed emergency medical unit with official status, but also the HEMS 
organizations in Finland are under review for official status. The physician-staffed EMS units 
and their operational areas in Finland are shown in Figure 1. 
 
Physician-staffed emergency medical units also serve as a 24 hour consultation facility for 
paramedics. In the Uusimaa area, all prehospital units, onboard ship’s nurses travelling with 
passenger vessels in the Baltic Sea and physicians working in the local out-patient clinics are 
able to contact the HEMS physician. Medi-Heli 01 in Helsinki area receives approximately 
4 800 emergency calls every year and Medi-Heli 02 in the Turku area about 1 600. Most of 
the calls concern the treatment of cardiac patients and pain medication for trauma patients 
(Eriksson and Högström, 2004).  
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Figure 1. The 24 h physician staffed EMS units in Finland. Circle represents the area unit is 
covering (30-60 minute flight time). 1. Helsinki City EMS with MICU, (founded in 1971), 2. 
Medi-Heli 01 HEMS (Helsinki area, 1992), 3. Sepe HEMS (Oulu area, 1995), 4. Medi-Heli 
02 HEMS (Turku area, 1999), 5. Ilmari HEMS (North-Savo area, 2002), 6. Medi-Heli Pete 
HEMS (Vaasa area, 2005). 
 
 
Administration of the EMS system 
 
Administration of the EMS systems in Finland is based on the autonomy of each health 
district. Each municipality is responsible for either producing prehospital health care 
themselves or it has to be arranged by some other organization, e.g. the fire brigade or private 
ambulance company (Harve and Silfvast, 2004; Statute, 1972). Each district must have a 
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physician in charge of basic health care and each hospital district must have a physician 
responsible for advanced prehospital care (Statute, 1994).  
 
2.2. Coronary Heart Disease (CHD) 
 
2.2.1. Progression of the disease  
 
Initiation of atherosclerosis 
 
The formation of atherosclerosis begins at a very early stage of human life (McGill et al., 
2000). Atherosclerosis starts with extracellular lipid accumulation, where small lipoprotein 
particles accumulate in the intima of the coronary arteries because of the atherogenic-rich diet 
(Kruth, 1997). Then the leucocytes enter the area, moving towards the artery endothelium and 
intima and begin to transform into foam cells by absorbing lipids (Gimbrone et al., 1995). 
Afterwards, smooth muscle cells begin to migrate and proliferate in the intima area evolving 
atheroma (Stary et al., 1995). Smooth muscle cells are stimulated by growth factors and this 
increases the production of collagen, which is an important substance in the plaque (Amento 
et al., 1991). The plaque can develop microcirculation, which may increase the growth of the 
atheroma (O'Brien et al., 1994). Finally, mineralization of the plaque occurs and the atheroma 
forms (Demer, 1995). 
 
 
The pathogenesis of AMI 
 
Acute thrombosis in the coronary artery is caused by disruption of the atherosclerotic plaque 
(Falk et al., 1995). This may happen in two different mechanisms: 1) the fibrous cap of the 
plaque may fracture, which causes the majority of the thrombosis (Falk et al., 1995), and 2) 
through the superficial erosion of the intima (Farb et al., 1996). In both cases, the blood 
circulating in the coronary artery can now be in contact either with the tissue factor inside the 
plaque, or with the subendothelial basement membrane, where the collagen platelets are 
activating and starting the thrombotic process. This process leads into a cascade where 
substances that promote platelet activation and aggregation as well as thrombin generation 
enter the ruptured area and begin thrombus formation, which in the worst case leads to sudden 
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thrombotic occlusion in the infarct-related coronary artery (Davies, 2000; Rosenberg and 
Aird, 1999).  
 
2.2.2. Risk factors of atherosclerotic disease  
 
Dyslipoproteinemia 
 
Several studies have shown that high serum cholesterol levels have an important role in the 
development of CHD (Conroy et al., 2003; Neaton, 1992). The overload of lipoproteins in the 
blood increases the risk of lipoproteins to accumulate in the intima of the coronary artery as 
the first step to atherosclerosis (Kruth, 1997). The treatment of hyperlipidemia is important in 
the prevention of CHD, and therefore in Finland new recommendations for the management 
of hyperlipidemia have been published (Tikkanen et al., 2004). 
 
 
Smoking 
 
Smoking increases the risk of coronary artery disease and atherothrombosis by several 
mechanisms. Smoking increases platelet aggregation (Fusegawa et al., 1999), causes coronary 
spasm (Sugiishi and Takatsu, 1993) and impairs coronary artery vasodilatation (Zeiher et al., 
1995). Smoking also influences multiple adverse haemostatic effects (Meade et al., 1987) and 
increases inflammatory markers (Tracy et al., 1997), which increase the risk of CHD. 
 
 
Hypertension 
 
Hypertension increases the risk of CHD (MacMahon et al., 1990). The mechanisms are 
probably due to pulsatile flow, endothelial cell dysfunction and smooth cell hypertrophy. It 
has been shown that each reduction of 5-6 mmHg in diastolic pressure reduces the risk of 
CHD by 14 % (Collins et al., 1990). 
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Diabetes and insulin resistance 
 
Up to 70 % of deaths among diabetic patients result from CHD (Gu et al., 1998). Diabetes 
increases the risk of cardiovascular events up to three to five-fold (Kannel and McGee, 1979). 
Hyperglycaemia increases the production of very low density lipoproteins (VLDL) in the liver 
whose end products increase the risk of vascular damage (Wautier and Guillausseau, 1998). 
Diabetic patients also have impaired endothelial and smooth muscle function (Stehouwer et 
al., 1992). Insulin resistance causes a prothrombic state, because it increases the levels of 
plasminogen activator inhibitor-1 (PAI-1) and fibrinogen (Reaven, 1997) and therefore also 
the risk of thrombotic process may increase in a partly occluded coronary artery . 
 
2.2.3. Acute Coronary Syndromes (ACS) 
 
Acute coronary syndrome is the clinical state where the patient suffers from ischemic 
myocardial symptoms. ACS can be divided into two categories: non ST-elevation and ST-
elevation diseases. Non-ST-elevation disease presents as unstable angina pectoris (UAP) or 
non-Q-myocardial infarction. ST-elevation disease may result in ST-elevation myocardial 
infarction (STEMI) leading to Q-wave-myocardial infarction or non-Q-myocardial infarction 
(Braunwald et al., 2000). 
 
The incidence of ACS increases with age and AMI results in higher mortality in elder patients 
than in younger patients. Up to 80 % of the patients dying due to AMI are older than 65 years 
(Wenger, 1992). In the GUSTO study, the in-hospital mortality varied from 3 % for patients 
younger than 65 years to 30 % for those older than 85 years (GUSTO, 1993). AMI may cause 
a depressive state in the patient whose recovery from the MI may be compromised. In elderly 
patients, depression has been shown to be common after AMI (Frasure-Smith et al., 1995; 
Milani and Lavie, 1998). The daily living functions after AMI in elderly patients is poorly 
known, and elderly patients seem to participate inadequately in rehabilitation programmes 
after the cardiac event (Evenson et al., 1998). 
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Clinical features of STEMI 
 
Patients suffering from AMI may have prodromal symptoms such as chest discomfort or 
angina pectoris (Stewart et al., 1997). When the coronary artery is occluded, the pain is 
usually very severe and intense and lasts for more than 20 minutes (Van de Werf et al., 2003), 
but symptoms may vary and the patient may only have symptoms from left ventricular failure, 
syncope or discomfort in the chest (Sheifer et al., 2000). Nausea and vomiting occur in many 
patients as well as weakness, dizziness and palpitations. In some cases, the patient does not 
feel the chest pain (silent myocardial infarction), which occurs more with patients suffering 
from diabetes or hypertension (McGuire and Granger, 1999). Diseases mimicking AMI most 
often originate from the musculoskeletal area of the chest, pericardium or from the 
oesophageal area (Goyal, 1996; Spodick, 1995).  
 
 
Electrocardiography findings and biochemical markers in STEMI 
 
The standard 12-lead electrocardiograph has remained a cornerstone in the detection and 
localization of AMI (Panju et al., 1998). In STEMI, the ECG criteria for thrombolytic therapy 
usually consists of ST-segment elevations of at least 1 mm in two or more limb leads, 2 mm 
in two or more precordial leads, or a new left bundle-branch block (GUSTO, 1993). However, 
ECG findings may be only relative and other diagnostic measures such as biochemical 
markers of cardiac damage are needed for the diagnosis (Van de Werf et al., 2003). When 
myocytes suffer from ischemia and become necrotic, intracellular macromolecules, better 
known as cardiac markers, are diffusing into the circulation (Adams et al., 1993). The most 
commonly used cardiac markers are creatine kinase, its cardiac-specific isoenzyme CK-MB 
and cardiac-specific troponins TnT and TnI (Adams et al., 1993; Alpert et al., 2000). They 
have different ranges of times to initial elevation, but within the first hours from myocardial 
damage the increase of all these cardiac markers can be seen (Alpert et al., 2000). 
 
 
Management of STEMI 
 
The management of STEMI consists of oxygen, antiplatelet therapy, analgetics, nitrates, beta-
blockers, and rapid revascularization of the occluded coronary artery by fibrinolytic substance 
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or percutaneous coronary intervention (PCI), or both (facilitated PCI) (Van de Werf et al., 
2003). Oxygen has a protective effect on the myocardium, and the administration of oxygen 
should start as soon as possible after the cardiac event (Maroko et al., 1975). Antiplatelet 
therapy with acetocalicytic acid (ASA) has been shown to be effective in reducing mortality 
(ISIS-2, 1988). It blocks the formation of thromboxane A2 in the platelets by cyclooxygenase 
inhibition and inhibits platelet aggregation (Patrono, 1994). The control of chest pain is also 
important to reduce sympathetic stimulus and the work of the heart. The pain is controlled by 
analgesics (e.g. morphine), oxygen, nitrates and beta-blockers (Van de Werf et al., 2003). 
Nitrates increase the coronary flow by dilating the coronary arteries and reducing the 
ventricular preload by reducing the venous capacitance (Jugdutt et al., 1989). Beta-blockers 
decrease the work load of the heart and reduce the need of oxygen, which can relieve the pain 
and reduce the size of infarction as well as reduce morbidity and mortality by, e.g. preventing 
malignant ventricular arrhythmias (Freemantle et al., 1999; MIAMI, 1985). These therapies 
may be beneficial also in the prehospital setting (Koefoed-Nielsen et al., 2002). 
 
2.2.4. Thrombolytic therapy 
 
Fibrinolytic system and thrombolysis 
 
Thrombolytic therapy in AMI is based on fibrinolysis (Collen, 1997). The cascade to produce 
fibrinolysis is a chain of several enzyme and proenzyme actions (Figure 2). The plasminogen 
activator plays a key role in fibrinolysis when the cascade is activated by fibrinolytic drugs 
such as streptokinase or t-PA (Lijnen, 1998).  
 
Proenzyme plasminogen is activated into the plasmin by plasminogen activator. Plasmin 
either degrades fibrin into soluble fibrin degradation products (FDP) in the fibrin surface 
(Thorsen, 1992) or activates fibrinogen, Factor V and Factor VIII in the fluid phase. 
Fibrinogen and Factors V and VIII then effect the degradation in the fluid face (Reddy, 1980). 
 
Fibrinolytic substances can be divided into two categories; they can improve the formation of 
plasmin by activating plasminogen in the fluid phase (fibrin specific agents) (Reddy, 1980) or 
they can activate fibrin to associate plasminogen in the fibrin surface (non-fibrin specific 
agents) (Hoylaerts et al., 1982).  
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Figure 2. Fibrinolytic system 
 
 
Thrombolytic agents  
 
Streptokinase 
 
Streptokinase is the oldest thrombolytic agent used in the thrombolytic therapy of AMI 
(Fletcher, 1958). It activates plasminogen indirectly by first forming an equimolar complex 
with plasminogen, then catalyzing the reaction where plasminogen transforms into plasmin 
and finally generating free circulating plasmin, which cannot be inhibited by α2-antiplasmin 
(Reddy, 1980) (Figure 2). This forms a systemic lytic state. The systemic antithrombotic 
effect continues for several hours and adjunctive therapy, such as heparin, in fibrinolysis is 
not needed. After the administration of streptokinase, antigens may  develop and therefore 
allergic reactions are possible if streptokinase is given again later (Squire et al., 1999). 
Previous streptococcal infection may also increase the number of neutralizing 
antistreptokinase antibodies in the blood, which may compromise the effect of streptokinase 
in AMI (Shaila et al., 1994). In addition, the decrease of systemic blood pressure during 
streptokinase-infusion has been reported (Green et al., 1984; Lew et al., 1985). 
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t-PA and variants 
 
t-PA is an ineffective enzyme, if fibrin is not available. If fibrin is present, t-PA enhances the 
activation of plasminogen, which results in the increase of plasmin formation at the fibrin 
surface (Hoylaerts, 1982) (Figure 2). Plasmin has also both its lysine binding and active sites 
occupied and therefore the α2-antiplasmin is not able to inhibit the formation of plasmin 
(Collen, 1980). These interactions are based on the fibrin-specificity of t-PA. Reteplase also 
has plasminogenolytic activity, but it is inhibited by plasminogen activator inhibitor-1 (PAI-1) 
(Kohnert, 1992). Tenecteplase has a similar ability to bind to fibrin-rich clots, but it is even 
more fibrin-specific and has a resistance to PAI-1 (Keyt, 1994; Modi, 1998).  t-PA and its 
variants do not develop antigens and therefore re-thrombolysis by these agents is safe. They 
all have a different elimination half-life and therefore the dosage is different in each of these 
thrombolytic agents (Table 1). 
 
Table 1. Comparison of different thrombolytic agents. 
Thrombolytic 
agent 
 
 
Fibrin-
specifity 
Elimination 
half-life 
(plasma) 
Dosage Antige- 
nicity 
Streptokinase 
 
 
- 20-25 min 1.5 MIU in 30-60 minute 
infusion 
++ 
Alteplase  
 
 
 
++ 4-8 min 15 mg bolus + 0.5 mg/kg 
in 60 minute infusion 
(max. 100 mg) 
- 
Reteplase 
 
+ 14-18 min 2 x 10 U 
30 min apart 
 
 
- 
Tenecteplase +++ 11-20 min One shot bolus 30-50 mg 
(0.5 mg/kg) 
- 
 
 
 
History of thrombolytic therapy in AMI 
 
The first study of the streptokinase in the thrombolysis of AMI was published in 1958 
(Fletcher, 1958). After that, the interest towards thrombolytic treatment in AMI increased. At 
the same time, also the first steps in coronary arteriography were taken (Sones, 1962) and 
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when the techniques to perform percutaneous coronary angiography improved, the first 
studies to administer thrombolytic agent direct to the intracoronary thrombus were performed 
(Chazov, 1976; Rentrop, 1979). 
 
In the 1980s, the investigation of systemic thrombolytic therapy of AMI was vigorous. Many 
large controlled trials were performed at this time (AIMS, 1988; GISSI, 1986; ISIS-2, 1988; 
Wilcox et al., 1988). The results of these trials are presented on Table 2. The results from all 
these trials showed a reduction in early mortality, and thrombolytic therapy became the 
“therapy of choice” for AMI (FTT, 1994). Later on the follow up study of the GISSI-I study 
also verified that the benefits sustained up to 10 years (Franzosi, 1998). 
 
Table 2.  In-hospital thrombolytic treatment for AMI, controlled trials in the 1980s. 
Study Design No of 
Patients 
Result 
 
GISSI 
1986 
 
1.5 MIU of streptokinase 
vs. placebo 
 
11 806 
 
21-day hospital mortality 10.7% vs. 13% 
in favour of streptokinase, p=0.0002 
 
ISIS-2 
1988 
 
 
 
1. 1.5 MIU streptokinase 
 
2. 160 mg aspirin for one 
month  
 
3. Both 
 
17 187 
 
5-week vascular mortality: 
1. 9.2% (SK) vs. 12.0% (placebo), 
p<0.00001 
2. 9.4% (aspirin) vs. 11.8% (placebo), 
p<0.00001 
3. 8.0% (SK+aspirin) vs. 13.2% (neither), 
p<0.001 
 
AIMS 
1988* 
 
 
 
30 units of anisoylated 
plasminogen streptokinase 
activator complex 
(APSAC) 
vs. placebo 
 
1004 
 
30-day mortality: 
6.4% vs. 12.2%,  
p=0.0016 in favour of APSAC 
 
ASSET
1988 
 
 
100 mg rt-PA + heparin 
vs. placebo + heparin 
 
13 318** 
5011 
 
30-day mortality: 
7.2% vs. 9.8%, p=0.0011 in favour of rt-
PA 
 
SK, streptokinase.  
* The study was terminated early due to ethical reasons, because the interim analysis showed 
a 47% reduction in 30-day mortality.  
** 8 307 patients were excluded from the study. 
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In 1993 streptokinase and accelerated tissue plasminogen activator (t-PA) was compared with 
subcutaneous and intravenous heparin in 41 021 patients (GUSTO, 1993). The result favoured 
t-PA over streptokinase in mortality, but the rate in haemorrhagic strokes was greater in the t-
PA group (0.54 % vs. 0.72 %, p=0.03). When the combined end-point of death and disabling 
stroke was studied, the t-PA group survived better than the streptokinase only groups (7.8 % 
vs. 6.9 %, p= 0.006).  
 
New fibrin specific substances were needed and they were derived from the recombinant 
tissue-type plasminogen activator (rt-PA, alteplase). The problem of rt-PA was the short half-
life and therefore the need for continuous infusion when administering the agent. Reteplase 
was a new fibrin specific thrombolytic agent, which could be given in two 10 U boluses 30 
minutes apart from each other (Bode, 1993). In 1995 the results of the INJECT study 
(n=6010) showed that double bolus reteplase was at least as effective and safe as 
streptokinase (INJECT, 1995). In this study, the rate of serious bleedings was comparable, but 
there were more strokes in the reteplase group (INJECT, 1995). In the GUSTO trial this was 
seen also with t-PA (GUSTO, 1993). 
 
Lanoteplase has also been under investigation. Lanoteplase is a fibrin specific thrombolytic 
agent. In the InTIME trials (den Heijer et al., 1998; InTIME-II, 2000) 120 kU/kg of 
lanoteplase was shown to be as effective as 100 mg of alteplase, but for some reason the 
number of strokes was significantly higher in the lanoteplase group. Lanoteplase has not been 
taken into therapeutic use for this reason. 
 
Tenecteplase is the latest derivative from rt-PA, which has come into the clinical use. The 
safety of this agent was shown in the TIMI-10B and the ASSENT-1 studies (Cannon, 1998; 
Van De Werf, 1999). The ASSENT-2 trial showed that a single bolus of weight-adjusted 
tenecteplase is as effective and safe as 100 mg of front-loaded alteplase (ASSENT-2, 1999). 
In the ASSENT-3 study, tenecteplase with enoxaparin was found to be a safe and feasible 
combination for thrombolytic therapy of AMI. The ongoing ASSENT 4 PCI- study is 
investigating tenecteplase as a thrombolytic agent in facilitated PCI (ASSENT-3, 2001). 
Tenecteplase is the only single-shot thrombolytic agent in clinical use at this time.  
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Adjunctive therapies in thrombolytic treatment 
 
Reocclusion is possible after fibrinolysis. Active plasmin breaks up only the fibrin from the 
surface of the clot (Figure 2). This is mainly due to thrombin and factor X, which both bind to 
the clot. Thrombocytes still remains in the clotted area. If some active thrombin and 
thrombocytes are revealed on the surface of the clot in the result of thrombolysis, reocclusion 
of the coronary artery may occur. Therefore, adjunctive therapies in fibrinolysis, such as 
antiplatelet therapy with aspirin, clopidogrel or GP IIb/IIIa antagonists and heparin (or its 
analogues) are needed to keep the coronary artery open after thrombolytic therapy. Moreover, 
the plaque rupture stimulates platelet activation and therefore platelet inhibitors are important 
drugs in preventing the thrombotic process (Fernandez-Ortiz, 1994). The optimal therapy with 
heparin is still under investigation, but it seems that low-molecular heparin has advantages 
over unfractionated heparin (ASSENT-3, 2001). However, there may be subgroups, such as 
elderly patients who may have increased risk of bleeding complications after thrombolytic 
therapy in conjunction with low-molecular weight heparin (Wallentin et al., 2003) and more 
studies are needed to find the optimized adjunctive therapy with PHT. Different 
antithrombotic therapies in AMI are shown in Table 3.  
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Table 3. Antithrombotic therapies in AMI 
Adjunctive agent 
 
Route Dose and dosage 
Aspirin Oral Load: 150-325 mg  
Maintenance: 75-150 mg daily 
 
Clopidogrel Oral Load: 300 mg  
Maintenance: 75 mg daily 
 
Glycoprotein 
IIb/IIIa antagonist, 
Abciximab 
 
Intravenous Load: bolus 0.25 mg / kg 
Maintenance: infusion 0.125 µg / kg / min  
12 hours after PCI 
Low-molecular 
weight heparin 
(e.g. enoxaparine) 
 
Intravenous 
Subcutaneous 
Load: bolus 30 mg 
Maintenance: 1 mg / kg x 2 / day 
Unfractionated 
heparin 
Intravenous Load: bolus 60 IU / kg, max.  4000 IU 
Maintenance: infusion 12 IU / kg , max. 1000 IU,  24 – 
48 h (aPTT: 50-70 s) 
 
aPTT, activated partial thromboplastin time. From the Task Forces on the management of 
acute myocardial infarction (Van de Werf et al., 2003) and percutaneous coronary 
interventions (Silber et al., 2005) of the European Society of Cardiology. 
 
 
Contraindications for thrombolytic therapy in AMI 
 
There are several contraindications to be considered before the start of the thrombolytic 
treatment for AMI. Contraindications are divided as absolute and relative, and the clinician 
has to consider these before the treatment. Contraindications for thrombolytic treatment are 
shown in Table 4. 
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Table 4.  Absolute and relative contraindications of thrombolytic treatment in AMI;. 
Absolute contraindications 
Haemorrhagic stroke or stroke of unknown origin at any time 
Ischemic stroke in preceding six months 
Central nervous system damage or neoplasms 
Recent major trauma / surgery / head injury (within preceding three weeks) 
Gastro-intestinal bleeding within the last month 
Known bleeding disorder 
Aortic dissection 
 
Relative contraindications 
Transient ischemic attack in preceding six months 
Oral anticoagulant therapy 
Pregnancy or within one week post partum 
Non-compressible punctures 
Traumatic resuscitation 
Refractory hypertension (systolic blood pressure > 180 mmHg) 
Advanced liver disease 
Infective endocarditis 
Active peptic ulcer 
 
From the Task Force on the management of acute myocardial infarction of the European 
Society of Cardiology (Van de Werf et al., 2003). 
 
 
Safety of thrombolytic therapy  
 
Thrombolytic therapy for AMI may cause adverse effects such as bleeding and 
haemodynamic disorders in spite of whether the patients are treated inside or outside the 
hospital setting. The most serious complications are intracranial haemorrhage (ICH) and 
stroke. The incidence of these varies from 0.5  to 3 % depending on the thrombolytic 
substance, the adjunctive therapies (ASSENT-2, 1999; EMIP, 1993; GREAT, 1992; INJECT, 
1995; GUSTO, 1993; ISIS-2, 1988; Ruiz-Bailen et al., 2005; Weaver et al., 1993; Wilcox et 
al., 1988), and  other risk factors such as age, body weight and hypertension (Gebel, 1998; 
Simoons et al., 1993). Streptokinase shows a trend towards a lower incidence of ICH than t-
PA variations. The risk of other major bleeding complications than ICH varies from 0.5 to 5.5 
%  and complications are likely to appear in covert bleeding areas such as the bowel, bladder 
and vascular puncture sites (ASSENT-2, 1999; EMIP, 1993; GISSI, 1986; GREAT, 1992; 
GUSTO, 1993; INJECT, 1995; ISIS-2, 1988; Weaver et al., 1993; Wilcox et al., 1988).   
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Arrhythmic adverse effects, such as ventricular fibrillation (VF) related to reperfusion has 
been observed in up to 8 % of all patients with intracoronary thrombolysis (Della Grazia et 
al., 1986). On the other hand, it has been suggested that ventricular tachycardia (VT) and VF 
are not markers for reperfusion after thrombolytic therapy and they are more likely to be 
caused by occluded artery and myocardial ischemia (Berger et al., 1993; Hackett et al., 1990). 
However, both VF and VT have been reported after administration of thrombolytic treatment 
(GISSI, 1986; Newby, 1998; Solomon et al., 1993). The time from pain to thrombolytic 
therapy may play some role in the incidence of ventricular arrhythmias (Boissel, 1996).  
 
Other arrhythmias and hypotension have been reported during and after thrombolytic therapy 
(Berger et al., 1992; GUSTO-III, 1997; ISIS-2, 1988). Bradycardia may cause problems 
during thrombolytic therapy (Berger et al., 1992; Koren, 1986). Hypotension especially with 
streptokinase have been reported in up to 10 % of patients (ISIS-2, 1988; Koren, 1986). 
Hypotension may in some cases result from allergic reactions, but anaphylactic shocks are 
rare during thrombolysis with streptokinase (GISSI, 1986; ISIS-2, 1988).  
 
2.2.5. Prehospital thrombolysis (PHT) 
History 
 
As early as the 1980s, when large trials of thrombolytic therapy were still going on, the 
importance of the delay from the occlusion of the coronary artery to thrombolytic therapy was 
debated. Several studies were published to suggest that PHT would have beneficial effects on 
patients’ survival (Applebaum et al., 1986; Bippus, 1987; Koren et al., 1985). The first 
randomized controlled trial of 25 patients receiving PHT with APSAC was published in 1987 
(Castaigne et al., 1987). The results indicated that PHT with APSAC is feasible and well-
tolerated in AMI patients. The same group continued by investigating the prehospital use of 
APSAC for AMI in 100 patients. The results were again promising but larger trials to study 
mortality were needed (Castaigne et al., 1989). In the studies by Roth (rt-PA, 118 patients) 
and Schofer (urokinase, 78 patients) there were significant time savings in favour of PHT, but 
they failed to show any clinical benefit from PHT (Roth et al., 1990; Schofer et al., 1990).  
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In 1992 the GREAT study group published a controlled trial of 311 AMI patients who were 
either prehospital treated with 30 mg of anistreplase by general practitioners working in the 
Grampian region of England, or received  thrombolytic therapy in the hospital (GREAT, 
1992). The pain-to-therapy delay was cut from 240 to 101 minutes, if thrombolytic treatment 
was given at home. There were fewer cardiac arrests and Q-wave infarcts in the prehospital 
group compared to the hospital group. Left ventricular function was also better (p=0.02) and 
mortality lower (p=0.04) in the prehospital group. The EMIP trial, which included 5 469 AMI 
patients treated with anistreplase, was the first study to convincingly show the decrease in 
overall mortality (EMIP, 1993). Although the trial failed to show any significant reduction in 
mortality, it did confirm that PHT was a safe and feasible method for treating AMI patients. 
The same result was found in the MITI trial, where 360 patients were studied in Seattle, USA 
(Weaver et al., 1993). In addition, the trial showed that treatment within 70 minutes from the 
start of the chest pain reduced the size of the infarction and complications. It was very clear 
that PHT could cut the delays from the start of the pain to thrombolytic therapy. Still, the 
studies failed to show a decrease in mortality.  
 
In 1996 Boersma and co-workers published data from all randomized trials with more than 
1 000 patients to show that early thrombolytic treatment up to two hours from randomization 
has a highly beneficial effect on mortality (Boersma et al., 1996). The survival curve from this 
study is presented in Figure 3. Now there was more evidence that the time from occlusion of 
the coronary artery to thrombolytic treatment was an important factor in survival from AMI. 
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Figure 3. Estimated benefit (lives saved at 35 days) per 1 000 patients treated with 
thrombolytic therapy in relation to pain-to-therapy time (Boersma et al., 1996) 
 
 
 
Finally, in 2000 the results of a meta-analysis of all randomized controlled trials of 
prehospital vs. in-hospital thrombolytic therapy suggested that PHT may reduce  in-hospital 
mortality (Figure 4) (Morrison et al., 2000). 
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Figure 4. All-cause hospital mortality by Morrison et al., 2000. Odds ratio is the ratio of the 
odds of mortality in the prehospital group to the odds in the in-hospital group.  
 
 
Delays in the treatment of AMI 
 
The total delay in the treatment of AMI with thrombolytic therapy includes the patient, the 
EMS and the hospital delays. It has been shown that nearly half of the AMI patients suitable 
for thrombolytic therapy are waiting up to three to four hours before calling for help 
(Bredmose et al., 2003; Weaver, 1995). Female and elderly (>65 years old ) patients have 
been reported to wait longer before calling for help than others (Leizorovicz et al., 1997). 
Media campaigns have been shown to have only marginal impact on the help-seeking delay 
(Caldwell and Miaskowski, 2002; Kildemoes and Kristiansen, 2004). Improvement of 
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prehospital management of AMI is expected to cut the delay in the call-to-therapy time 
(Goldstein and Wiel, 2005). Short prehospital EMS door-to-therapy time may save time for 
the patient, but the time benefit also comes from rapid transportation to the hospital.  
. 
 
 
 
 
 
 
 
 
 
Figure 5. Delays in the treatment of AMI 
 
 
Prehospital thrombolytic therapy performed by paramedics 
 
Most cases of death associated with AMI occur during the first hour from the occlusion of the 
coronary artery, which emphasizes the importance of prehospital management of AMI 
(National-group, 1994). PHT was previously performed by physicians (Castaigne et al., 1989; 
EMIP, 1993; GREAT, 1992). However, it has been shown that also nurses and paramedics are 
able to recognize the ECG changes in AMI and perform thrombolytic therapy (Foster et al., 
1994; Keeling and, 2003; Pitt, 2002; Qasim et al., 2002; Ruiz-Bailén, 2001; Welsh et al., 
2004). To perform PHT, paramedics need to send the ECG to the physician. The technical 
possibilities of sending an ECG from the field to the hospital have been available since the 
1980s (Grim et al., 1987). The prehospital ECG has also been shown to improve the in-
hospital management of patients suffering from acute MI, even if the ECG has not been 
transmitted to the hospital before the patient admittance (Canto et al., 1997). If the prehospital 
ECG has been transmitted to the hospital, door-to-needle times are shorter in the hospital 
(Terkelsen et al., 2002; Wall et al., 2000). Understanding the different variations of 
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prehospital systems and possibilities to perform PHT will significantly reduce the time to 
thrombolytic therapy (Welsh et al., 2004). 
 
Thrombolytic treatment after cardiopulmonary resuscitation 
 
Thrombolytic treatment after cardiopulmonary resuscitation (CPR) has been much debated, 
because CPR has been a relative contraindication to thrombolytic treatment (Van de Werf et 
al., 2003). In three retrospective studies, the rate of bleeding complications varied from 3 to 
10 %, and only few fatal hemorrhagic complications were seen (Kurkciyan et al., 2003; Ruiz-
Bailén, 2001; Voipio et al., 2001). In a study by Ruiz-Bailén et al., mortality and the need for 
mechanical ventilation as well as cardiogenic shock were less frequent  in the thrombolyzed 
patient group compared to the group that did not receive thrombolytic treatment (Ruiz-Bailén, 
2001). In keeping with this, Kurkciyan et al. showed that the bleeding complications were 
common but they were not related to the duration of the resuscitation (Kurkciyan et al., 2003). 
In a prehospital study, Voipio et al. showed that only few patients who were resuscitated and 
thrombolyzed before admittance to the hospital suffered from serious bleeding complications, 
and as many as 53 % of all patients were discharged from the hospital (Voipio et al., 2001). 
Recent meta-analysis suggests there is a trend that thrombolytic therapy after CPR stabilizes 
patients and probable bleeding risks do not outweigh the benefits (Spohr and Bottiger, 2003). 
 
2.2.6. Percutaneous coronary intervention (PCI) 
 
The first percutaneous transluminal coronary angioplasty was performed in 1977 (Gruentzig, 
1979). Reperfusion is achieved by using a guide wire and balloon catheter, which is guided 
through the thrombus and at the same time the coronary lumen is enlarged by the balloon 
(Roubin et al., 1988). In most cases, also a metal stent is placed into the occluded coronary to 
maintain the coronary flow and avoid restenosis (Erbel et al., 1998; Mehta et al., 2005).  
 
The possible superiority of PCI over thrombolytic therapy has been under serious debate 
(Stone, 2002) and several studies have been published to show the superiority of PCI 
(Andersen et al., 2003; Aversano et al., 2002; Bednar et al., 2003; Widimsky et al., 2003). 
However, the superiority of PCI over thrombolytic therapy has also been challenged 
(Bonnefoy et al., 2002; Steg, 2003; Stern et al., 2003). PCI has been suggested to be better 
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treatment compared to immediate thrombolytic therapy even if the patients should be 
transferred to another hospital. In the DANAMI-2 study, the primary endpoints were a 
composite of death, reinfarction and disabling stroke. The endpoint-free survival was better in 
the PCI group than the thrombolysis group (8.5 % vs. 14.2 %, p=0.002) (Andersen et al., 
2003). Patients receiving PCI may also have improved long-term survival than patients 
treated by thrombolytic therapy (Henriques et al., 2005). According to studies favouring 
primary PCI, thrombolytic therapy, also in the prehospital setting, should be avoided and the 
patients should be transferred to the nearest angioplasty centre to receive primary PCI even if 
the pain-to-therapy  delay increases up to three hours (Andersen et al., 2003; Bednar et al., 
2003; Dalby et al., 2003; Widimsky et al., 2003). This would decrease the mortality, 
reinfarctions and disabling strokes as much as 38 to 42 % compared to thrombolytic therapy. 
Subanalysis from the PRAGUE-1 study also suggested that the transfer for AMI patients 
complicated by acute heart failure to receive PCI is safe and improves the clinical outcome 
(Bednar et al., 2003). 
 
Some studies do not favour PCI over thrombolytic therapy. The CAPTIM study randomized 
patients to receive either PHT or PCI in less or more than two hours after symptoms 
(Bonnefoy et al., 2002). There were no differences between the groups in a 30-day combined 
primary endpoint of death, nonfatal reinfarction or disabling stroke. The same data analyzed 
in another study by Steg et al. showed that there was a trend towards lower mortality in the 
PHT group, if the treatment was given in less than two hours from the symptoms. The authors 
concluded that the time factor should be considered when selecting reperfusion therapy for 
STEMI patients (Steg, 2003). Also in the pilot study by Stern et al., very early thrombolytic 
therapy seemed to cause a higher extent of early myocardial reperfusion compared to PCI 
(Stern et al., 2003). 
 
Sometimes PCI is needed as rescue treatment after thrombolytic therapy, if the occluded 
coronary artery has not opened with thrombolytic therapy. It has been shown that prolonged 
pain-to-therapy times are associated with impaired myocardial perfusion detected in rescue 
PCI as well as increased mortality, which amplifies once again the importance of reducing 
delays of treatment in AMI (Gibson et al., 2004). In addition, if thrombolytic therapy is 
contraindicated to the patient, PCI should be done (Van de Werf et al., 2003). 
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Facilitated PCI (the combination of thrombolytic therapy and PCI) is an interesting possibility 
to start the treatment in STEMI early with a thrombolytic agent and then complete the 
treatment in the hospital with PCI (Kelly et al., 2004). The ASSENT 4 PCI study is enrolling 
4 000 patients first to receive tenecteplase followed by PCI and the FINESSE trial with 3 000 
patients is using a reduced dose of reteplase in combination with or without abciximab before 
PCI  (Ellis et al., 2004). The results of these trials will provide more information on the 
indication of facilitated PCI. In areas with long distances (e.g. in Northern Finland) this may 
be one solution to improve the treatment of patients suffering from AMI.  
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3. AIMS OF THE STUDY 
 
The aim of this thesis was to study the prehospital management of AMI in a helicopter-based 
EMS system. The specific aims were the following: 
 
1. To evaluate the feasibility and reliability of various modes of transmission of the ECG 
from the field to the physician for diagnostic assessment. (I) 
 
2. To evaluate the effect of prehospital physician involvement in the EMS system with 
special reference to the treatment of STEMI patients (II) and to describe the 
possibilities for prehospital personnel to perform PHT with on-line physician 
consultation. (III) 
 
3. To assess the occurrence of adverse events associated with PHT. (IV) 
 
4. To evaluate the effectiveness of PHT in elderly patients with special reference to the 
patients’ mental and physical status during follow-up. (V)  
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4. MATERIALS AND METHODS 
 
4.1. EMS systems in Helsinki, Turku and Pirkanmaa areas 
 
The Medi-Heli Helicopter Emergency Medical Service (HEMS) System operates from two 
different bases; one is located in the capital area surrounding the city of Helsinki with 850 000 
inhabitants (Helsinki City 560 000 inhabitants excluded) and the other in the area of the city 
of Turku (520 000 inhabitants, increasing up to 600 000–650 000 inhabitants during the 
summer season). Both units are ready to dispatch in three minutes 24-hours a day. In case of 
bad weather or mission located near the HEMS base, both units are able to use a medical car. 
The HEMS crew consists of an emergency physician, a flight medic and a pilot. The area 
coverage in both HEMS is approximately 31 000 square kilometres, which means a 30-minute 
flight time. The Turku area HEMS respond to 1 500 primary missions every year and Helsinki 
area HEMS to 1 900. Only a few secondary missions are made every year. Local EMS is 
capable of basic and advanced life support in both operating areas and in life-threatening 
emergencies there is always a local EMS unit to co-operate with HEMS. Patients are 
transported to the nearest appropriate hospital or to the university hospitals of Helsinki or 
Turku by ambulance. Transportation by HEMS is an exception that is used only in the islands 
of the Turku archipelago. 
 
The Pirkanmaa area is situated in South-Central Finland, around the city of Tampere. There 
are 200 000 inhabitants in the city of Tampere and 250 000 inhabitants in the surrounding 
area of Pirkanmaa. In the Pirkanmaa area there are no physician-staffed prehospital units. 
During the time of the study (II) there were no general prehospital instructions for medical 
emergencies for the paramedics or ambulance crews. If the patient was suffering from cardiac 
problems, the electrocardiogram was not necessarily obtained. PHT had not been introduced 
to the area. Only half of the patients received thrombolytic therapy in the out-patient clinics 
and rest of the patients were transported to Tampere University Hospital.  
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4.2. Patients  
 
Altogether, 641 patients who suffered from STEMI and received thrombolysis either in the 
Helsinki area HEMS or at Tampere University Hospital between January 1st 1997 and 
December 31st 1999 were included in the study II. Studies IV and V included all patients who 
suffered from STEMI between June 2000 and November 2001 and were treated by Helsinki 
and Turku area HEMS. The inclusion criteria for thrombolytic therapy were age more than18 
years, duration of the symptoms over 30 minutes, ST-segment elevations of least 1 mm in two 
or more limb leads, or at least 2 mm in two or more precordial leads, or development of a new 
left bundle-branch block in a 12-lead ECG. Patients were not eligible for thrombolytic 
therapy, if they had head trauma or major surgery within two months or a known history of 
stroke. On addition, transient ischemic attack, bleeding disorders or active bleeding and 
pregnancy were contraindications for thrombolytic therapy. Hypertension of more than 180 
mmHg after treatment with nitrates or beta-blockers or prolonged cardiopulmonary 
resuscitation with suspicion of multiple rib fractures were also considered as contraindications 
for thrombolysis. The one-year mortality was detected from the National Population Register. 
An autopsy was not performed on all patients who died within the first year of myocardial 
infarction. 
Study III describes two patients who suffered STEMI in a passenger ship and received 
thrombolytic therapy from a ship’s nurse after consulting the HEMS physician. 
 
4.3. Study protocols and treatments 
 
4.3.1. Electrocardiogram transmission (I) 
 
Paramedics from the Tuusula Fire Department randomly collected 18 authentic ECG 
recordings with a Life-Pak 12 (LP unit) monitor defibrillator (Medtronic PhysioControl 
Corp., Redmont, USA), which was the maximum number of ECGs the monitor defibrillator 
could store in its memory. The transmissions consisted of 5 ECGs with AMI, 2 with 
myocardial ischemias, 1 with ventricular tachycardia, 2 with early repolarization, 3 with 
bradycardia, and 4 with no abnormalities. One ECG with misplaced limb leads was 
deliberately included. 
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These 18 ECGs were sent from the LP unit connected to a Nokia 6150 mobile phone (Nokia 
Mobile Phones, Nokia, Finland) to three receiving devices: 1) a Brother 9050 Table Laser Fax 
(Brother Industries, USA); 2) a Nokia N9210 Communicator, and 3) to a Lifenet RS 
Receiving Station (Medtronic Physio-Control Corp., USA). After that the ECGs were printed 
out from the LP unit in the Tuusula Fire Department and paper printouts were transmitted 
from a Possio PM 70 Mobile Fax and Phone (Possio AB, Sweden) connected to the mobile 
phone. These recordings were transmitted to the Table Fax and to the advanced mobile phone. 
 
Later the same 18 ECG printouts that the paramedics from the Tuusula Fire Department had 
printed out from LP unit were sent by ordinary post mail to the ship’s nurse onboard m/s 
Amorella (Viking Line, Åland Isles, Finland). She copied the two-sheet ECG recordings onto 
one A4-size sheet. This is constantly done on the ship, because A4-paper fits the Canon L-250 
Laser Fax (Tokyo, Japan) they are using for transmissions. ECGs were then transmitted as an 
A4-copy from a Laser fax connected to a satellite phone system via Intelsat 707 Satellite to 
the Table Fax and to the advanced mobile phone located at the HEMS base. The ship was 
sailing during the transmissions. 
 
Finally, the same A4-printouts the ship’s nurse had copied were sent by post mail to an 
outpatient clinic. From there, a paramedic sent the ECGs from a Harris 3M 2220 table 
facsimile machine (Atlanta, GA, USA) to the Table Fax and to the advanced mobile phone at 
the HEMS base. The study protocol is shown in Figure 6. 
 
All the transmission times were measured. Afterwards, two EMS physicians independently 
evaluated and graded all the ECGs for: 1. Overall quality; 2. Possibility to recognize the 
cardiac rhythm by identification of the P-wave, 3. The ST-segment changes. The criteria used 
for overall quality were from 1 (poor) to 5 (good).  
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Figure 6. Study protocol (I) 
 
 
 
4.3.2. Influence of physician involvement on management of ST-elevation myocardial 
infarction (II) 
 
In the Helsinki area, the EMS conducted the primary survey of the patients, administered 
supplemental oxygen to all patients and measured the oxygen saturation with pulse oximetry. 
The ECG was monitored continuously and the patients’ arterial blood pressure was measured 
non-invasively. After the diagnosis of STEMI, patients were given 250 mg of acetylsalicylic 
acid orally and if there were no contraindications, thrombolytic treatment was started by 
streptokinase, alteplase or reteplase. The thrombolytic substance used was chosen by the 
physician on a clinical basis.  If the patient was in pain, morphine was administered 
intravenously. In case of cardiac arrest, the first ECG was recorded approximately 30 min. 
after the return of spontaneous circulation. Clinically relevant hypotension considered by the 
physician was treated first with intravenous fluids and dopamine infusion, if necessary. 
Bradycardia was treated with atropine and also external pacing was available. Adrenaline was 
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administered only during or immediately after CPR. Hypertension was treated with nitrates 
and beta-blockers. Ventricular tachycardia and extra systoles were treated with intravenous 
beta-blockers. 
 
In the Pirkanmaa area there were no general prehospital instructions for the treatment of 
STEMI patients. It was impossible to describe the treatment given before arrival to the 
hospital, because the information from the patient and the treatments in the prehospital 
running sheets were insufficient. Most of the paramedic units located outside the Tampere 
city area were instructed to go to the local health centre with the STEMI patient before 
starting transportation to Tampere University Hospital. Also in the Tampere City area, some 
of the patients were first transported to a health centre by ambulance. In Tampere University 
Hospital, thrombolytic therapy was given in the emergency room. The treatment of the 
patients suffering from STEMI was the same as prehospital treatment in the Helsinki area, but 
also lanoteplase 15–120 kU per kg body weight was used as a thrombolytic agent. 
 
4.3.3. Thrombolytic therapy performed by a ship’s nurse with on-line physician 
consultation (III) 
 
All consultations the HEMS physician receives are documented in the electronic files at the 
HEMS base. The physician is engaged to fill in all relevant information from the consultation, 
such as the consulting unit and person, relevant time intervals, patient’s anamnesis and status 
as well as given instructions including prescriptions of drugs. On-line consultation is used, if 
the HEMS cannot get to the scene because of the weather conditions or if the location is too 
distant from the HEMS base. During on-line consultation, the phone line is open until the 
existing problem has been solved. Ships’ nurses and HEMS physicians involved in the 
treatment of the patients described in the study III were interviewed by one of the authors 
(OV).  
 
4.3.4. Evaluation of arrhythmias and haemodynamic effects (IV)  
 
Altogether, 226 patients were prospectively studied. The patients were divided into two 
groups: the patients who received thrombolytic therapy early (< 90 min) and late (> 90 
minutes from the start of the pain). Patients were treated with the same principles as patients 
in the physician EMS in the study II, but only reteplase was used as a thrombolytic agent. 
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After initiation of thrombolysis and stabilization of the patient, transportation by ambulance 
to the closest appropriate hospital was started. During the prehospital phase, a structured data 
collection form was filled in by the HEMS physicians. All rhythm disturbances as well as 
non-invasive blood pressure, heart rate and oxygen saturation was monitored after every five 
minutes and the therapies given during the entire prehospital phase were recorded. Any other 
rhythm than a sinus rhythm was defined as arrhythmia. Extrasystolias were also recorded. All 
relevant time intervals and delays were recorded to the HEMS running sheets. 
 
4.3.5. Quality of life of the elderly patients (V) 
 
The study consisted of 218 patients suffering from STEMI. The patients were regarded as 
elderly if they were > 65 years old. Reteplase was used as the thrombolytic agent and the 
principles of the prehospital treatment of the patients were the same as in study II. All patients 
were transported to the hospital after receiving thrombolytic treatment by HEMS on the 
scene. The HEMS physician escorted the patients to the hospital and recorded all adverse 
events on the structured form. A normal HEMS running sheet was used to record the patients’ 
vital signs. After 4-6 months from hospital discharge one of the researchers (OV) or a 
research a nurse contacted the patient by phone to assess the present Barthel Daily Living 
Index and New York Heart Association (NYHA) score (Kossman, 1964; Mahoney and 
Barthel, 1965). The Barthel Daily Living Index measures simple daily activities such as 
eating, walking, moving, personal hygiene, bathing, dressing and the control of bowel and 
bladder. After the phone contact, the patients received a Beck inquiry form by ordinary mail 
to fill in (Beck et al., 1961). The Beck inquiry is an instrument designed to measure the 
behavioural manifestations of depression. The questions deal with sadness, pessimism, sense 
of failure, dissatisfaction, guilt, dislike of self, suicidal ideation, social withdrawal, 
indecisiveness, the change in body image, work inhibition, fatigability and the loss of 
appetite. The patients filed in the inquiry by themselves. The one-year mortality was detected 
from the National Population Register. 
 
4.3.6. Ethical aspects 
 
The study protocols were approved by the institutional review board of Helsinki University 
Hospital. Before the patient entered the study (IV, V), the HEMS physician explained the 
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study protocol to the patient and the patient signed the informed consent. If the patient was 
unable to sign the consent the permission for the study was requested from the next of kin. 
 
4.3.7. Statistical methods 
 
Statistical calculations were made using the SPSS versions 10 or 11 (SPSS Inc, Chicago, IL, 
USA). Because the data were not normally distributed, the Wilcoxon or Mann-Whitney 
nonparametric tests were used. Fisher’s exact test was used to compare categorical variables. 
A two-tailed p-value below 0.05 was considered as significant. 
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5. RESULTS 
 
5.1. Transmission of the electrocardiogram (I)  
 
The transmission times are shown in Figure 7. The physicians could recognize the cardiac 
rhythm and ST changes in all ECGs except one. The best quality ECGs were those 
transmitted directly from the LP-12 unit connected to the mobile phone (Figure 8). There 
were some transmission difficulties in all study groups. Altogether, 13/72 (18 %) initial 
transmission attempts to the advanced mobile phone and 10/72 (14 %) to the table fax failed. 
In contrast, one transmission to the Lifenet RS receiving station failed. After 1–3 attempts, all 
ECGs were successfully transmitted. The actual problem was to receive the initial contact 
between transmitting and receiving devices, but when the contact was established there were 
no transmission problems. With all devices, the number of transmission failures was 
comparable.  
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Figure 7. The transmission times (min) between the devices. LP 12: Advanced mobile phone 
vs. Lifenet RS, p < 0.0001, table fax vs. Lifenet RS, p<0.01. Canon laserfax: advanced mobile 
phone vs. table fax, p<0.01 
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Figure 8. Quality of transmitted ECGs graded as 1-5 (poor-good). Harris table fax: advanced 
mobile phone vs. table fax, p<0.001 
 
 
5.2. Influence of physician-directed EMS on management of ST-elevation 
myocardial infarction (II, III) 
 
The study comprised 641 patients, including 263 in the physician EMS and 378 in the non-
physician EMS. The demographics of the patients are shown in Table 5. The pain-to-therapy 
delay was significantly shorter in the physician EMS (Table 5). The door-to-therapy times 
were similar (Table 5). The knowledge of the time frames was better documented in the 
physician EMS; the onset of pain was not known in only 6 patients (2 %) compared to 101 
patients (27 %) in the non-physician EMS (p<0.001). No differences were found in the need 
of invasive procedures, complication rates, hospitalization times or in one-year mortality 
(Tables 5,6). There were more patients receiving thrombolytic therapy after CPR in the 
physician EMS than in the non-physician EMS (52 patients (20 %) vs. 2 patients (0.5 %)). 
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Altogether, 31 (60 %) of the resuscitated patients in the physician EMS were discharged from 
the hospital, 23 of them (44 %) with good neurological recovery (Cerebral Performance 
Category (CPC) = 1). The recovery of the successfully resuscitated and surviving patients in 
the non-physician EMS group was also good (Table 7).  
 
The PHT performed by the ship’s nurse onboard the passenger vessel resulted in a good 
outcome in both cases (III). Patient 1 had a short period of VF before PHT, but one 
defibrillation with 200 J returned a sinus rhythm and the patient regained consciousness. 
There were no further problems during the PHT. The patient suffered from short episode of 
third-degree atrioventricular block and atrial arrhythmias in the hospital, but they were 
haemodynamically insignificant. She was discharged from the hospital two weeks after the 
event in good condition. Patient 2 suffered a short period of VF at the time of PHT, which 
was successfully treated by one 120 J defibrillation. No further adverse events occurred 
during the PHT. In the hospital, she had short runs of haemodynamically stable VT. She was 
discharged from the hospital 10 days after the event with ejection fraction > 60 % measured 
by echocardiography.  
 
5.3. Evaluation of adverse events (IV)  
 
Altogether 226 patients were included in the study (146 treated by the Helsinki Area HEMS 
and 80 by the Turku Area HEMS). The characteristics and pain-to-therapy times are shown in 
Table 5. Fifteen patients were given thrombolysis after CPR. Seven of them were discharged 
from hospital, all except one with good neurological recovery. One patient suffered from 
cardiac arrest after initiation of thrombolysis and died before admission to hospital. 
 
Hypotension was relatively common (21 % of all patients) in both groups. The majority of the 
patients suffering from hypotension in both groups were hypotensive on the arrival of the 
EMS (68 % of the hypotensive patients in the early thrombolysis group and 65 % in the late 
thrombolysis group). The rest of the hypotensive patients (7 % of patients in both groups) 
became hypotensive during thrombolytic treatment. From the patients who received CPR, 40 
% were hypotensive after the arrest and they all required treatment for hypotension (systolic 
blood pressure < 100 mmHg); 3 patients received fluids, 2 dopamine-infusion and 1 patient 
received adrenaline boluses. 
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Out of all patients, 39 % had arrhythmias (40 % in the early and 38 % in the late thrombolysis 
group), but only 33 % of them required treatment with antiarrhythmic drugs or defibrillation 
(38 % in the early and 24 % in the late thrombolysis group). The most common arrhythmia 
was ventricular extra systoles (52 % in the early vs. 46 % in the late thrombolysis group), but 
the need for treatment was rare (7 % vs. 12 %, respectively). Half of the patients who needed 
treatment because of arrhythmia suffered from bradycardia (38 % in the early and 24 % in the 
late thrombolysis group). The most common treatment for bradycardia was atropine. All VF 
patients were defibrillated and thy also received an antiarrhytmogenic drug.  
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Figure 9. Arrhythmias in early (first bar) and late (second bar) thrombolysis. The proportions 
are from all patients (n = 226). 
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Table 5. Characteristics of the patients in studies II, IV and V. 
 Study II Study IV Study V 
Characteristic 
 
Physician  
EMS 
Non-
physician  
EMS 
 
p < 90 min > 90 min p < 65 
years 
> 65 
years 
p 
Patients  
  (female / male) 
263 
 (73/190) 
378  
(113 / 265) 
 
 129 
(34/ 95) 
97 
(30 / 67) 
 106  
(16 / 90) 
112  
(44 / 68) 
 
Age (years) 
  (Mean + SD) 
 
63 + 12  
(25-88) 
67 + 12  
(35-95) 
<0.001 61 + 11  
(36-85) 
66 + 11  
(37-90) 
0.07 54 + 8  
(36-64) 
72 + 5 
 (65-90) 
<0.001 
Medical history 
  Prior CHD 
  Prior myocardial 
  infarction 
  Hypertension 
  Diabetes 
  Hypercholestero-  
  lemia 
  Congestive heart 
  failure 
 
 
53 (20%) 
57 (22%) 
 
77 (29%) 
32 (12%) 
17 (6%) 
 
15 (6 %) 
 
132 (35%) 
98 (26 %) 
 
111 (29%) 
61 (16%) 
30 (8%) 
 
34 (9%) 
 
<0.001 
ns 
 
ns 
ns 
ns 
 
ns 
 
43 (33%) 
30 (23%) 
 
34 (22%) 
10 (8%) 
16 (12%) 
 
10 8%) 
 
40 (42%) 
20 (21%) 
 
30 (31%) 
11 (11%) 
11 (11%) 
 
5 (5%) 
 
ns 
ns 
 
ns 
ns 
ns 
  
ns 
 
 
27 (25%) 
15 (14%) 
 
30 (28%) 
17 (16%) 
13 (12%) 
 
3 (3%) 
 
49 (44%) 
30 (27%) 
 
31 (28%) 
21 (19%) 
15 (10%) 
 
12 (11%) 
 
0.004 
0.019 
 
ns 
ns 
ns 
 
0.03 
Previous medication 
  ASA 
  Nitro 
  Beta-blocker 
  Insulin 
 
76 (29%) 
78 (30%) 
87 (33%) 
10 (4%) 
 
119 (31%) 
156 (41%) 
147 (39%) 
10 (3%) 
 
ns 
0.011 
ns 
ns 
 
 
32 (25%) 
34 (26%) 
40 (31%) 
9 (7%) 
 
29 (30%) 
37 (38%) 
32 (32%) 
11 (11%) 
 
ns 
0.06 
ns 
ns 
 
 
18 (17%) 
23 (22%) 
25 (24%) 
10 (9%) 
 
37 (33%) 
42 (38%) 
42 (38%) 
8 (7%) 
 
0.008 
0.011 
0.027 
ns 
Location of  
infarction 
  Anterior 
  Inferior 
  ST-elevation prior  
  to thrombolysis  
  (mm) 
 
 
131 (50%) 
118 (45%) 
13 + 10 
(0-53) 
 
 
161 (43%) 
154 (41%) 
10 + 9  
(0-61) 
 
 
ns 
ns 
<0.001 
 
 
61 (48%) 
62 (48%) 
12+9 
(1-53) 
 
 
52 (55%) 
38 (40%) 
12+8 
0-48) 
 
 
ns 
ns 
ns 
 
 
47 (44%) 
55 (52%) 
12 + 8 
 (1-46) 
 
 
59 (53%) 
44 (39%) 
12 + 9  
(2-53) 
 
 
ns 
0.074 
ns 
 
Haemodynamics at 
admission 
  Systolic blood 
  pressure (mmHg) 
  Diastolic blood 
  pressure (mmHg) 
  Heart rate (1 / min) 
 
  Oxygen saturation 
  (%) 
 
 
126 + 32  
(50-210) 
84 + 20  
(30-180) 
75 + 20  
(30-150) 
97 + 3  
(80-100) 
 
 
142 + 30 
 (60-240) 
80 + 20  
(30-180) 
76 + 20  
(30-140) 
93 + 11  
(63-100)  
 
 
<0.001 
 
ns 
 
ns 
 
0.023 
 
 
130 + 30 
(60-215) 
80+20 
(40-125) 
75 + 25  
(35-180) 
97 + 6 
(40-100) 
 
 
140 + 30 
(70-230) 
80+20 
(40-140) 
80 + 20 
(30-150) 
96 + 7 
(42-100) 
 
 
ns 
 
ns 
 
ns 
 
ns 
 
 
130 + 35  
(60-215) 
80 + 20  
(40-140) 
70 + 20  
(35-140) 
98 + 2  
(92-100) 
 
 
 
140 + 35  
(70-230) 
80 + 20  
(40-125) 
80 + 25  
(30-180) 
95 + 10  
(40-100) 
 
 
 
0.028 
 
ns 
 
0.017 
 
0.009 
Invasive actions 
  Angiography 
  PCI 
  CABG 
 
 
8 (3%) 
18 (7%) 
11 (4%) 
 
23 (6%) 
28 (7%) 
14 (4%) 
 
0.092 
ns 
ns 
 
8 (6%) 
29 (22%) 
5 (4%) 
 
9 (9%) 
24 (25%) 
2 (2%) 
 
ns 
ns 
ns 
 
 
9 (8%) 
34 (32%) 
4 (4%) 
 
8 (7%) 
16 (14%) 
3 (3%) 
 
ns 
<0.001 
ns 
Positive biochemical 
markers ** 
 
214 
(81%) 
332 
(88%) 
ns 117 
(91%) 
84 
(87%) 
ns 96 
(91%) 
104 
(93%) 
ns 
Pain-to-therapy time  
(min) 
 
124 +101 
(25-723) 
196 + 150 
(12-835) 
<0.001 60 + 18 
(20-90) 
173 + 89 
(91-500) 
<0.001 108 + 93  
(27 –500) 
108 + 70 
(20-357) 
ns 
EMS door-to- 
therapy time (min) 
38 + 17 
(7-112) 
39 + 38* 
(7-297) 
ns 30 + 14  
(5-67) 
36 + 17  
(4-76) 
ns 31 + 14  
(4-71) 
 
33 + 16  
(7-76) 
 
ns 
 
 
Data shown in italics are unpublished. Data shown in bold indicate the significant differences. 
CABG, Coronary Artery Bypass Surgery 
* Hospital door-to-therapy time 
** Either CK-MB, TnT or TnT-I  
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Table 6. Survival and recovery from AMI from studies II, IV and V.  
 Study II Study IV Study V 
Characteristic 
 
Physician  
EMS 
Non- 
physician  
EMS 
p < 90 min > 90 min p < 65 
years 
> 65 years p 
Patients  
  (female / male) 
 
263 
 (73/190) 
378  
(113/265) 
 129 
(34 /  95) 
97 
(30 / 67) 
 106  
(16 / 90) 
112  
(44 / 68) 
 
One-year  
mortality 
 
52 (20%) 
 
55 (15%) 
 
0.106 
 
15 (12%) 
 
16(16%) 
 
ns 
 
7 (7%) 
 
24 (22%) 
 
0.002 
 
Cause of the  
death 
  Cardiac 
  Other 
  Unknown 
 
 
 
40 (77%) 
4 (8%) 
8 (15%) 
 
 
41 (75%) 
3 (5%) 
11(20%) 
 
 
ns 
ns 
ns 
 
 
14 (93%) 
1 (7%) 
 
 
 
11(69%) 
5 (31%) 
 
 
 
0.05 
ns 
 
 
5 (5%) 
2 (2%) 
 
 
20 (18%) 
4 (4%) 
 
 
0.003 
ns 
Treatment times  
in hospital 
   Length of  
   CCU/ICU  
   stay (days) 
  Length of  
  Hospitalization 
  (days) 
 
 
 
4 + 3  
(0-18) 
 
10 + 7  
(0-50) 
 
 
4 + 4  
(1-31) 
 
10 + 6 
 (1-48) 
 
 
ns 
 
 
ns 
 
 
4 + 3 
(1-25) 
 
10 + 6 
(3-44) 
 
 
3 + 2 
(1-18) 
 
9 + 3 
(1-16) 
 
 
ns 
 
 
ns 
 
 
3 + 3  
(1-25)  
 
9 + 5  
(4-44) 
 
 
4 + 3  
(1-16)  
 
10 + 6  
(1-39) 
 
 
0.066  
 
 
ns 
Complications  
  Bleeding 
     Internal  
     bleeding 
     Haematoma 
  ICH 
 
 
17 (6%) 
 
16 (6%) 
1 (0.4%) 
1 (0.4%) 
 
23 (6%) 
 
19 (5%) 
4 (1%) 
1 (0.3%) 
 
ns 
 
 
 
ns 
 
 
14 (11%) 
 
8 (6%) 
6 (5%) 
0 (0%) 
 
2 (2%) 
 
2 (2%) 
0 (0%) 
2 (2%) 
 
 
0.016 
 
 
 
ns 
 
6 (6%) 
 
3 (3%) 
3 (3%) 
1 (0.9%) 
 
10 (9%) 
 
2 (2%) 
8 (7%) 
1 (0.8%) 
 
ns 
 
 
 
ns 
 
Data shown in italics are unpublished. Data shown in bold indicate the significant differences. 
CCU, Coronary Care Unit; ICU, Intensive Care Unit 
 
 
5.4. Evaluation of the quality of life of the elderly patients (V)  
 
Altogether, 218 PHT patients were evaluated for survival and recovery. From these patients, 
106 were considered as younger (< 65 years old) and 112 as elderly (>65 years old). The 
demographic data of the patients are shown in Table 5. The one-year mortality of all patients 
was 14 % (if resuscitated patients were excluded, 11 %). The elderly patients had a higher 
one-year mortality compared with the younger patients (22 % vs. 7 %, p=0.002). The most 
common cause of death was cardiac (Table 6).  
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After the initial event, 91 % of patients were contacted at 4–6 months. There were no 
significant differences in the Beck Depression Inventory  (< 65 years: 6 + 6 (range 0 - 26) vs. 
> 65 years: 5 + 5 (0-23)) and the Barthel Index (< 65 years: 99 + 5 (range 65 - 100) vs. > 65 
years: 98 + 12 (10-100)) between the groups, but the NYHA score was better among the 
younger patients (1.6 + 0.9 (range 1 - 4) vs. 1.8 + 0.9 (1-4), p=0.048).  
 
Fifteen patients received CPR prior to PHT (nine in the elderly and six in the younger patients 
group). Of these patients, three in the elderly (33 %) and four in the younger (67 %) group 
survived. All survivals except one in the younger group had a cerebral performance category 
1 (good recovery) at discharge (Table 7). None of the patients had a Barthel Index < 35 
suggesting severe disability. In addition, according to the BDI scale, only one patient suffered 
from moderate depression at the time of the interview. None of the resuscitated and 
discharged patients died during the first year after the event. 
 
Table 7. Resuscitated patients from the studies II and V. 
 Study II 
 
Study V 
 Physician EMS 
 
Non- physician 
EMS 
< 65 years > 65 Years 
No of resuscitated patients 
 
52 / 263 (20%) 
 
2 / 378 (0.5%) 
 
6 / 106 (6%) 9 / 112 (8%) 
Prehospital death 
In hospital death 
Alive after one year from the 
event  
6 (12 %) 
15 (29 %) 
29 (56 %) 
0 (0 %) 
1 (0.5 %) 
1 (50 %) 
 
0 (0%) 
2 (33%) 
4 (67%) 
 
0 (0%) 
6 (67%) 
3 (33%) 
 
CPC at the time of discharge 
from hospital 
        1 
        2 
        3 
        4 
 
 
 
23 (44%) 
1 (2%) 
1 (2%) 
6 (12%) 
 
 
 
1 (50%) 
 
 
3 (50%) 
0 (0%) 
1 (17%) 
0 (0%) 
 
 
 
3 (33%) 
0 (0%) 
0 (0%) 
0 (0%) 
 
Invasive actions 
  Angiography 
  PCI 
  CABG 
 
3 
2 
1 
 
1 
0 
0 
 
0 
3 
0 
 
0 
0 
0 
Treatment times in hospital 
  Length of  CCU/ICU 
  stay (days) 
  Length of hospitalization 
  (days) 
 
 
4 + 3  
(0-18) 
11 + 8  
(0-33) 
 
17 + 13 
(7-26) 
19 + 10 
(12-26) 
 
6 + 2 
(5-9) 
22 + 16 
(5-44) 
 
4 + 2 
(1-7) 
9 + 7 
(1-19) 
Complications  
  Bleeding 
     Internal bleeding 
     Haematomas 
  ICH 
 
7 (13%) 
7 (13 %) 
0 (0 %) 
0 (0%) 
 
0 (0%) 
0 (0 %) 
0 (0%) 
0 (0%) 
 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
 
3(33%) 
1(11%) 
2 (22%) 
0 (0%) 
 
Data shown in italics are unpublished. CABG, Coronary Artery Bypass Surgery; CCU, 
Coronary Care Unit; ICU, Intensive Care Unit 
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6. DISCUSSION 
 
6.1. Transmission of the electrocardiogram 
 
In a case where the prehospital personnel suspects a STEMI, a physician should be contacted 
and the ECG transmitted for the evaluation before starting PHT (Van de Werf et al., 2003). It 
has been shown that transmission of ECG by cellular telephone connected to a portable ECG 
machine is feasible (Grim et al., 1987). This provides a way to shorten the pain-to-therapy 
delays and improve in-hospital management of patients suffering from acute MI (Canto et al., 
1997; Terkelsen et al., 2002; Wall et al., 2000). Leibrandt et al. showed that decisions for 
reperfusion therapy can be made using cellular telephone with advanced features and 
facsimile possibility (Leibrandt, 2000). Also continuous telemetry has been studied in order to 
reduce delays in thrombolytic therapy, but so far the benefits have been limited and more data 
is needed from these systems (Woollard et al., 2005). In this study (I) the focus was on the 
speed and reliability of the ECG transmissions with various transmitting and receiving 
devices. The possibility of a mobile receiving facility is essential in a busy EMS system or in 
a hospital, where physicians should be able to receive ECG transmission without being in one 
particular place where the receiving facsimile machine is located. The quality of the EGC in 
the advanced mobile phone was found to be good and completely readable. Only one rhythm 
was not recognized by the other physician evaluating the films. An advanced mobile phone 
can be a useful tool for the consultant to evaluate prehospital ECGs. However, in some 
HEMS systems the use of cellular phone is totally forbidden during the flight and it is also 
impossible to speak to the advanced mobile phone while it is receiving fax transmission. 
There also may be some difficulties when transmitting the ECG from a moving vehicle or 
from locations where the coverage of the mobile phone network is poor. These problems can 
be solved by stopping the ambulance during transmission or moving on to find a stronger 
mobile phone network. In this study, transmission was finally successful in all cases.  
 
6.2. Influence of physician involvement 
 
The treatment of patients suffering from AMI involves both prehospital and in-hospital 
organizations. However, it has been shown that the recommendations and current practice do 
not always meet in Europe (Hasdai et al., 2002) and that the patients do not receive the 
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recommended treatment. PHT is associated with a four-fold increase in aborted MI (Lamfers 
et al., 2003), but patients do not activate the EMS system in acute cardiac problems or activate 
it too late and this may compromise the time benefit from the PHT (Canto et al., 2002). 
Introduction of PHT in the EMS system mandates medical involvement and guidance. In the 
USA and Canada there have been guidelines for medical control in EMS since the 1990s 
(Polsky et al., 1993; Thompson and Curry, 1993). In Finland, no common guidelines on 
medical direction in EMS have been issued so far (Langhelle et al., 2004). Of the two 
participating EMS systems in this thesis (II), one had no common instructions for EMS and 
there were no physicians in operative work. The other had physicians working in the field and 
guiding the operational work in their area. The delays for thrombolytic therapy were shorter in 
the physician EMS because the treatment was performed on the scene. Some patients also 
received thrombolytic therapy after CPR. Also outpatient clinics co-operated with the HEMS, 
and patients received thrombolytic therapy by the HEMS in the out-patient clinic. 
 
6.3. Consultation possibilities for nurses and paramedics to perform 
prehospital thrombolysis   
 
In many EMS systems there are no physicians available on the scene and the  PHT is 
performed by others than physicians (Keeling and, 2003; Pedley, 2003; Svensson et al., 2003; 
Welsh et al., 2004). It has been shown that paramedics are able to identify the right patients 
for thrombolytic treatment  (Pitt, 2002; Whitbread, 2002). Indeed, it has been suggested that 
the safety of PHT is not connected to the presence of a physician (Welsh et al., 2005). We 
showed that one possibility to provide PHT is by on-line physician consultation (III). 
Although the nurses worked alone under difficult conditions on the passenger vessel, they 
were able to successfully treat patients suffering from STEMI and VF. The nurses were 
trained to treat STEMI patients with thrombolytic therapy after consultation by an HEMS 
physician. Fortunately, the consultation call was in progress in both cases, so the physician 
was able to give on-line instructions for the nurses to go on with the treatment. The recovery 
of both patients was good, suggesting effective and appropriate treatment by the ship’s nurse 
with minimal delays. Similar prehospital consultation systems for ships’ nurses have not been 
reported earlier. In Finland the need for advice to prehospital personnel exists, but still only 
part of the country is covered by a 24 h consultation system run by physicians specialized in 
prehospital work (Langhelle et al., 2004).   
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6.4. Delays in prehospital thrombolysis 
 
The delay from pain to thrombolytic therapy has a great impact on the survival of  patients 
with AMI (Boersma et al., 1996). Thrombolytic treatment within two hours seems to improve 
survival from AMI (Chareonthaitawee et al., 2000). Early PHT has been reported to have also 
positive long-term effects (Danchin et al., 2004; Weiss et al., 1998). It has been estimated that 
delaying thrombolytic treatment by one hour increases the risk of death by 20 % and a 30-
minute delay reduces the average expectation of life by one year (Rawles, 1997). Kroese et al. 
showed that, if 45 minutes can be cut from the call-to-needle time, 61 cases need to be treated 
to save one additional life at 35 days (Kroese et al., 2004). In study II, the pain-to-therapy 
delay was significantly shorter in the physician EMS, and an extra 70 minutes were saved by 
PHT. The pain-to-therapy delays have decreased ever since and present delays in the Helsinki 
and Turku area HEMS are comparable to other prehospital studies (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Pain-to-therapy times in in-hospital and prehospital studies. 
 
In the study by Hirvonen et al., the pain-to-therapy time was 160 minutes (Hirvonen et al., 
1998). The study was conducted over three months, with a total of 1 012 patients studied and 
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48 out of 51 hospitals attended the study, suggesting most of the AMI patients receiving 
thrombolytic therapy in Finland during that time participated in the study. Only some of the 
patients received PHT and most of the patients were transferred to the hospital to receive 
thrombolytic therapy. Compared to the study by Hirvonen et al., Helsinki area HEMS could 
save 40 minutes for the patients by treating the patients immediately instead of taking them to 
the hospital. It is estimated that PHT performed by Turku area HEMS saves 70 minutes in the 
urban areas and up to two hours in the rural areas (Luukkanen et al., 2003). It seems that an 
effective way to decrease the pain-to-therapy time in sparsely populated Finland is to start 
prehospital thrombolysis by paramedics under a physician’s guidance.  
 
Door-to-therapy delays have also been studied with a view to shortening the total delay before 
thrombolytic therapy. It has been shown that the in-hospital delay from door to thrombolytic 
therapy can be shortened if the paramedics have taken a prehospital ECG (Canto et al., 1997) 
or if the treatment is initiated by the nurse instead of a physician (Qasim et al., 2002). Also in-
hospital training programmes can improve the treatment of STEMI patients by shortening the 
door-to-needle times (Palomäki, 2001). 
 
6.5. Complications and adverse effects of prehospital thrombolysis 
 
Complications such as ventricular tachyarrhythmias (Boissel, 1996; GISSI, 1986; Newby, 
1998; Solomon et al., 1993), bradycardia (Berger et al., 1992; Koren, 1986) and hypotension 
(ISIS-2, 1988; Koren, 1986) during or after in-hospital thrombolytic treatment are well 
known. Less is known about arrhythmias and haemodynamic adverse events during or after 
PHT, where the time from coronary occlusion to thrombolytic therapy is often shorter. In the 
present study (IV), 40 % of the patients suffered from arrhythmias, but of those patients only 
38 % in the early and 24 % in the late study groups needed treatment. The most common 
arrhythmia was ventricular extrasystoles, which seldom needed any treatment. Serious 
arrhythmias such as VF were seen in 2.5 % of the patients. The incidence of VF was similar 
in the studies by Roth and Svensson (Roth et al., 1990; Svensson et al., 2003). Compared to 
the EMIP trial and the study by Schofer et al., the incidence of prehospital VF was lower in 
our study (2.5 % vs. 4–5 %) (EMIP, 1993; Schofer et al., 1990). All episodes of VF were 
successfully treated by defibrillation and medication. The clinical impact of VF in 
thrombolytic therapy is still unknown and it is not clear whether VF is a sign of reperfusion or 
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not (Berger et al., 1993; Della Grazia et al., 1986; Goldberg et al., 1983; Solomon et al., 
1993).  
 
Bradycardia occurred in 10 % of the patients in this study (IV) and 80 % of bradycardic 
patients were suffering from inferior infarction. Most often it was treated with atropine, but 
one patient also needed external pacing. In previous studies, the occurrence of bradycardia 
during PHT has varied between 4 and 15 % (GREAT, 1992; Roth et al., 1990; Schofer et al., 
1990). Bradycardia may also cause hypotension, which was seen also in our study. Of all 
hypotensive patients in this study, 13 % received atropine. Hypotension occurred in 14 % of 
all patients before thrombolytic therapy and 7 % after the start of PHT, respectively. In 
previous prehospital studies hypotension related to the initiation of PHT has not been 
reported, but the overall incidence of overall hypotension has been between 4–13 % 
(Castaigne et al., 1989; GREAT, 1992; Schofer et al., 1990). In some cases, hypotension may 
have been caused by the thrombolytic agent and hypotension has been documented up to 10 
% in patients receiving streptokinase (ISIS-2, 1988). Today, streptokinase is seldom used in 
the prehospital setting. 
 
Only a few patients received PHT after CPR in this study and these patients tended to be 
hypotensive after CPR. Other serious arrhythmias did not occur. Similar findings have been 
reported also by Voipio et al. (Voipio et al., 2001). There were no significant differences in 
haemodynamic complications or arrhythmias between the resuscitated and other patient 
groups. Hence, it seems that thrombolytic therapy is not associated with the increased risk of 
arrhythmic adverse events after successful resuscitation. 
 
Arrhythmias and haemodynamic problems do occur during and after PHT. Therefore, it is 
important that prehospital personnel are fully aware of these risks, the patients are well 
monitored during the entire prehospital phase, and – in case of adverse events – treatment is 
administered without delay.  
 
Bleeding complications may be serious, such as ICH.  The risk of haemodynamic problems is 
small if the bleeding site can be compressed, but if the bleeding is internal, blood transfusions 
are often needed. In keeping with previous reports (ASSENT-2, 1999; EMIP, 1993; GREAT, 
1992; GUSTO, 1993; INJECT, 1995; ISIS-2, 1988; Weaver et al., 1993; Wilcox et al., 1988) 
the rate of ICH in the study (II,V) was less than 1 % and other serious bleeding occurred in 
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about 6 % of the patients. Interestingly, those patients who received thrombolytic therapy < 
90 minutes from the start of the pain had more bleeding complications than those who were 
treated > 90 minutes from the start of the pain (IV).  
 
Cardiopulmonary resuscitation has been a relative contraindication for prehospital 
thrombolysis because of the possible risk of adverse bleeding events (Van de Werf et al., 
2003). However, in several in-hospital and prehospital studies, it has been shown that 
thrombolytic therapy after CPR is relatively safe and does not increase the rate of serious 
bleeding complications (Kurkciyan et al., 2003; Ruiz-Bailén, 2001; Spohr and Bottiger, 2003; 
Voipio et al., 2001). Although in this thesis there were only a limited number of patients who 
received thrombolytic therapy after CPR, our data supports the previous findings that serious 
adverse bleeding events are relatively uncommon. 
 
6.6. Elderly patients and prehospital thrombolysis  
 
Age has been proposed to be an important and independent factor for mortality among 
patients suffering from first myocardial infarction treated by thrombolytic therapy (Maggioni 
et al., 1993). They receive thrombolytic therapy less often than the younger (Barakat et al., 
1999; Kaplan et al., 2002) although the benefits of thrombolytic therapy for elderly patients 
are obvious (Gottlieb et al., 1997; Stenestrand and Wallentin, 2003; White et al., 1996). 
Strong opinions against current cardiac care of elderly patients have been presented (Gollub, 
1999; McMechan and Adgey, 1998). However, PHT of the elderly has not been studied as 
much as in-hospital thrombolytic therapy because most prehospital studies have excluded 
elderly patients (Castaigne et al., 1989; Roth et al., 1990; Schofer et al., 1990; Weaver et al., 
1993). In study V, prehospital thrombolytic treatment was equally effective in both age 
groups. In the elderly group there was at least a 50 % reduction in the ST segment elevation 
sum in 59 % of the patients, compared to 68 % in the younger patient group (p=ns). The mean 
delay from thrombolysis to the second ECG obtained in hospital was 61 vs. 54 minutes, 
respectively. It has been shown that ST segment resolution of 50 % is an independent 
predictor of combined outcome of mortality (Shah et al., 2000) and ECG taken 60 minutes 
after the start of the thrombolytic therapy predicts clinical outcome as well as ECG taken later 
(Purcell et al., 1997). It seems that, in this study, PHT resulted in a good outcome also in the 
elderly patients.  
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In the present study (V), elderly patients’ initial recovery from STEMI was as good as 
younger patients. However, one-year mortality was higher in the elderly group in this study 
(22 % vs. 7 %), but fully comparable to those reported previously (Gottlieb et al., 1997; 
Stenestrand and Wallentin, 2003; White et al., 1996). Compared to the Finnish AMI registry 
data, the mortality in this study was lower (7 vs. 10 % in the patients < 65 years old and 22 vs. 
34 % in the patients > 65 years old) (Häkkinen et al., 2002). The influence of PHT with 
minimal delays in low mortality cannot be excluded.  
 
Recent studies comparing PCI and thrombolytic therapy suggest that PCI is favourable 
compared to thrombolytic therapy in the elderly (Goldberg et al., 2003; Mehta et al., 2004), 
but in the meta-analysis by Mehta et al. this could not be confirmed (Mehta et al., 2005). 
Indeed, more trials are needed to find the most suitable reperfusion strategy for elderly 
patients. All these studies were done with in-hospital thrombolytic therapy and the effect of 
PHT with a shorter pain-to-therapy time remains to be established.  
 
The mechanism linking acute MI and depression is unknown (Ziegelstein, 2001). It has been 
shown that 9 % of AMI patients have moderate or severe depression and in a 24-week follow 
up depression is reported in up to 10 % of selected patients (Crowe et al., 1996). Depression 
may affect mortality after AMI (Frasure-Smith et al., 1995). In previous studies it has been 
suggested that age does not affect the risk of becoming depressive after AMI (Frasure-Smith 
et al., 2000). On the other hand, male patients younger than 65 years have been shown to have 
a tendency towards depression after AMI (Ladwig et al., 1991). In this study, patients younger 
than 65 years tended to be more depressive than the elderly patients measured by the Beck 
Depression Inquiry (Beck et al., 1961).  
 
It is important that elderly patients after AMI are able to continue their ordinary life with 
unlimited function of daily activity. The Barthel index, which measures the functions one 
needs every day, such as dressing, eating and taking care of personal hygiene, was similar 
among the younger and the elderly patients after PHT for AMI  (Mahoney and Barthel, 1965).     
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6.7. Prehospital thrombolysis vs. percutaneous coronary intervention  
 
PCI in the treatment of STEMI instead of thrombolytic therapy has been recently under 
debate. Studies favouring PCI over thrombolytic therapy as well as critical studies 
questioning the superiority of PCI have been published (Andersen et al., 2003; Bednar et al., 
2003; Bonnefoy et al., 2002; Hartwell et al., 2005; Steg, 2003; Stern et al., 2003; Stone, 2002; 
Widimsky et al., 2003). A recent meta-analysis suggests that patients should be transferred to 
the nearest PCI laboratory instead of instant thrombolytic treatment (Dalby et al., 2003). It 
may be that one has to consider the delay from the onset to the therapy when deciding the 
strategy of revascularization (Gersh et al., 2005; Steg, 2003). In the Helsinki and Turku 
HEMS areas, this debate is of importance since 74 % of the patients receiving thrombolytic 
therapy in this study had it within two hours and 58 % within 90 minutes. On the basis of the 
recommendations of the European Society of Cardiology and the results of the recently 
finished, but unpublished study in Helsinki area (HAAMU), which compared glycoprotein 
IIb/IIIa antagonist facilitated primary PCI and PHT, Helsinki and Uusimaa Health District 
now recommends primary PCI instead of PHT if the delay from the start of the pain is more 
than three hours and it is possible to perform PCI within 90 minutes from the first contact to 
the EMS (Silber et al., 2005; Van de Werf et al., 2003). 
 
In Finland, Helsinki University Hospital is still the only hospital in Finland that can provide 
24 h service for PCI. There are facilities in all of the five university hospitals and in several 
central hospitals to perform PCI, but the lack of cardiologists performing PCI limits the 
activity. It is possible that some hospitals also need improvements in the organization to be 
able to provide prompt PCI for patients suffering from AMI (Silber et al., 2005). In the meta-
analysis by Dalby et al., the suggested upper time limit for primary PCI is three hours (Dalby 
et al., 2003). Finland is a large country and transportation distances even in Southern Finland 
are easily up to 200 kilometres. The situation in Eastern and Northern Finland is even worse. 
Therefore, it is possible to perform primary PCI within three hours from the onset of pain 
only to the patients living in the vicinity of university or central hospitals. This means that 
PHT will remain the only possibility to reduce the delay in the treatment of STEMI in most of 
the areas in Finland for a long time to come. Moreover, facilitated PCI with different time 
strategies (PCI immediately in the hospital – during the first 24 hours) may change the 
management of AMI patients. 
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7. LIMITATIONS OF THE STUDY  
 
In study I, the number of transmitted ECGs was limited to 18 because the memory of the 
LP12 monitor defibrillator could not store more ECGs at the same time. Authentic ECGs and 
only one transmitting device were used to minimize the confusing factors. All the ECGs were 
sent in the same session. Two different telephone operators (Sonera, Radiolinja) were used. 
This may have caused some error in transmitting times or in the number of failed 
transmissions.  
 
Study II was retrospective. Comparison of the prehospital data between the Pirkanmaa and 
Helsinki area EMS was difficult, because the EMS in Pirkanmaa is not used to fill detailed 
ambulance running sheets and the hospital did not store the running sheets. It is not known 
how many of the STEMI patients died in the ambulance before entering hospital because of 
the lack of the prehospital data. Likewise, the exact number of resuscitated patients who 
received thrombolytic therapy in the ICU of Tampere University Hospital was not known. An 
EMS system without the possibility of PHT was used as a control group, because there was 
no EMS system available where paramedics were allowed to give thrombolytic therapy.  
Some of the patients also in the HEMS area were thrombolyzed in the hospital, because the 
HEMS unit was busy on another mission or grounded due to weather conditions and the 
distance to the patients by car would have been too long.   
 
In study IV, there were no options for Holter recordings. It is possible that some of the post-
thrombolytic arrhythmias have been missed because of that. There were also too few 
resuscitated patients to make any kind of statistical comparisons.  
 
In study V, the diagnosis of STEMI was done on a clinical basis and in some cases the 
markers showing myocardial damage did not increase in the blood. This may be due to 
inaccurate diagnosis or rapid treatment of the STEMI. Moreover, 9 % of the patients were not 
reached for the interview. It is possible that they were either mentally ill or physically in too 
poor shape for the interview.  
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8. CONCLUSIONS  
 
This study is focused on prehospital management of STEMI. The main conclusions of the 
study are:  
 
1. An advanced mobile phone is a fairly reliable instrument to receive ECG transmitted from 
different facsimile devices. An advanced mobile phone is also a feasible ECG interpretation 
tool for the consulting physician who needs the possibility to be mobile 24 h a day. 
 
2. A physician-directed EMS system is able to treat patients suffering from STEMI more 
effectively than a non-physician EMS system.  A well organized, physician-directed EMS 
system may also provide thrombolytic therapy to a larger group of patients than a non-
physician EMS system. With on-line emergency physician consultation, it may be possible for 
prehospital personnel working in isolated circumstances to perform PHT successfully on 
patients suffering from STEMI, even if the situation is complicated by VF.   
 
3. Arrhythmias and haemodynamic adverse events are common during and after PHT for 
STEMI. These side effects are usually easy to treat and serious adverse events are seldom. 
Thrombolysis after CPR does not seem to increase the incidence of these adverse events. PHT 
seems to be a safe and feasible method of treating patients suffering from STEMI. 
 
4. Elderly patients’ (>65 years old) initial survival from STEMI is almost as good as younger 
patients (< 65 years old) after PHT. Elderly patients’ quality of life including mental status 
remains at the same level compared to younger patients measured by BDI and the Barthel 
Daily Living Index, but one-year mortality is higher among the elderly. 
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9. FUTURE PERSPECTIVES 
 
9.1. Physician involvement in the EMS systems and EMS co-operation with 
the Invasive Cardiology Units 
 
More emergency physicians should be assigned to the EMS to increase the medical 
knowledge in the EMS systems. These physicians should guide and if possible, attend to the 
operational work in the EMS system. This could be one way to improve the quality of EMS 
systems. In the future, the need for co-operation between the EMS and the invasive 
cardiology units will increase. The management of patients suffering from AMI are 
improving, e.g. due to the primary and facilitated PCI. This emphasizes the importance of 
good local guidelines to produce the best treatment for AMI patients. This is possible only 
through collaboration of the EMS personnel and cardiologists. 
 
9.2. Reperfusion strategies in the EMS systems and PHT performed by 
paramedics 
 
In the future, more attention should be paid to finding the best reperfusion strategy for 
different STEMI patients in each EMS system. More studies on PCI vs. PHT as well as 
facilitated PCI for this contribution are needed. The impact of the delay from coronary 
occlusion to different reperfusion therapies as well as the meaning of different patient 
characteristics (weight, age, gender and the risk of bleeding) should be clarified, because they 
may play some role when selecting the most preferable reperfusion therapy for patients 
suffering from STEMI. Also, new thrombolytic agents and adjuvant therapies may change the 
protocols for prehospital care of STEMI patients. 
 
Paramedics should have training and permission to perform PHT. In this thesis, it has been 
shown that the evaluation of the ECG is possible through telemetry, and an emergency 
physician or a cardiologist can reliably receive an ECG to an advanced mobile phone. The 
permission for thrombolytic therapy can be given at the same time the ECG is evaluated. The 
rate of adverse events in the PHT is small and haemodynamic problems and arrhythmias are 
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usually easy to treat. This should encourage physicians to suggest PHT to paramedics and 
nurses.  
 
9.3. Consultation possibilities for prehospital personnel 
 
More professional consultation facilities for prehospital personnel are needed in Finland and 
more effort should be made to form larger consultation areas, where emergency physicians 
could take the responsibility for the consultations. These high-quality consultation service 
system offices could be located either in the EMS / HEMS systems or in the dispatching 
centres. More sophisticated and reliable telemetric devices should also be developed for EMS 
systems, because improved data collection and transmission are needed for the consultant. 
Consultation service systems could also help paramedics to perform the best reperfusion 
strategy for the patients suffering from AMI with minimal delays, especially in areas were 
distances are extensive. 
 
9.4. Helicopter Emergency Medical Service system in Finland 
 
In Finland there are good possibilities to construct an HEMS system to cover the whole 
country, because several HEMS systems are already in operation. After extensive discussions, 
it finally seems that health districts are taking the responsibility for the medical action in 
HEMS, and the HEMS systems will have full official status. In the future, HEMS physicians 
should guide more the prehospital work of the different EMS. Moreover, the education 
facilities for physicians and paramedics in HEMS should be extended.  
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INQUIRY FORMS  
 
Barthel- rehabilitation index 
 
Feeding  Help is absolutely necessary   0 
  Some help is necessary    5 
  Independent     10 
 
Moving from  
chair to bed Bed patient     0 
  Patient can come to a sitting position, 
needs to be lifted out of bed   5 
  Minimal help is needed    10 
  Independent     15 
 
Personal toilet Needs help     0 
(wash face,  Independent     5 
comb hair, shave,  
clean teeth) 
 
Getting on and Help is absolutely necessary   0 
off toilet  Some help is necessary     5 
  Independent     10 
 
Bathing self Needs help     0 
  Independent     5 
 
Walking on the Bed patient     0 
level surface Is able to push wheelchair 50 m   5 
  Needs help or supervision, walks 50 m  10 
  Can walk at least 50 m without help  15 
 
Ascend and No      0 
descend stairs Needs help     5 
  Independent     10 
 
Dressing Help is absolutely necessary    0 
  Needs help      5 
  Independent     15 
 
Continence of  Completely incontinent    0 
bowels  Occasionally incontinent    5 
  Is able to control his bowels   10 
 
Controlling Completely incontinent or catheter   0 
bladder  Occasionally incontinent, no catheter  5 
  Is able to control his bladder   10 
 
  Maximum points 100. Altogether              _________p. 
 
 
NYHA  1 (no symptoms)    2 (chest pain in uphill road )    3 (chest pain in level surface)   4 (chest pain in rest) 
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Beck Depression Inventory (BDI) 
 
This is an inquiry form that has 13 question groups (A-M). In every question group there are 
four different alternatives. Please read all these alternatives carefully before answering them. 
Then choose one alternative from each question group, which describes best your feelings 
today. Please mark the number beside the chosen alternative. If several alternatives are 
suitable, please mark them all.  
 
 
Name:_________________________________ 
 
Mood 
3  I am so sad or unhappy that I can’t stand it  
2  I am blue or sad and I can’t snap out of it  
1  I feel blue or sad  
0  I do not feel sad 
 
Pessimism  
3  I feel that the future is hopeless and that things cannot improve 
2  I feel I have nothing to look forward to 
1  I feel discouraged about the future 
0  I am not particularly pessimistic or discouraged about the future  
 
Sense of failure 
3  I feel I am a complete failure as a person (parent, husband, wife) 
2  As I look back on my life all I can see is a lot of failures 
1  I feel I have failed more than the average person 
0  I do not feel like a failure 
 
Lack of satisfaction 
3  I am dissatisfied with everything 
2  I don’t get satisfaction out of anything any more 
1  I don’t enjoy things the way I used to 
0  I am not particularly dissatisfied 
 
Guilty feeling 
3  I feel as though I am very bad or worthless 
2  I feel quite guilty 
1  I feel bad or unworthy a good part of the time 
0  I don’t feel particularly guilty 
 
Self hate 
3  I hate myself 
2  I am disgusted with myself 
1  I am disappointed in myself 
0  I don’t feel disappointed in myself 
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Self-punitive wishes 
3  I would kill myself if I could 
2  I have definitive plans about committing suicide 
1  I feel I would be better off dead  
0  I don’t have any thoughts of harming myself 
 
 
Social withdrawal 
3 I have lost all my interest in other people and don’t care about them at all 
2 I have lost my interest in other people and have little feeling for them  
1  I am less interested in other people now than I used to be  
0  I have not lost interest in other people  
 
Indecisiveness 
3 I can’t make new decisions at all any more  
2 I can’t make decisions any more without help  
1 I try to put off making decisions  
0 I make decisions about as well as ever  
 
Body image 
3 I feel that I am ugly or repulsive looking 
2 I feel that there are permanent changes in my appearance and they make me look 
   unattractive  
1 I am worried that I am looking gold or unattractive  
0 I don’t feel I look any worse than I used to 
 
Work inhibition 
3 I can’t do any work at all 
2 I have to push myself very hard to do anything  
1 It takes extra effort to get started at doing something 
0 I can work about as well as before 
 
Fatigability 
3 I get too tired to do anything 
2 I get tired from doing anything 
1 I get tired more easily than I used to  
0 I don’t get any more tired than usual  
 
Loss of appetite 
3 I have no appetite at all any more 
2 My appetite is much worse now 
1 My appetite is not as good as it used to be 
0 My appetite is no worse than usual 
  
 
 
